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ABSTRACT 
 
Background: Multiple sclerosis (MS) is a neurodegenerative disease of central nervous 
system with strong inflammatory component, which represent the main cause of clinical damage. 
Several risk factors have been associated with MS onset and progression such as vitamin D level, 
virus infections, smoke and obesity. However, the role of drugs exposure in MS development is 
still under-investigated. 
On the other hand, an important aspect of MS management is represented by safety of 
authorized therapies. In the past, these therapies have been associated with occurrence of 
unexpected adverse drug reaction (ADR) and recently case reports have documented idiosyncratic 
liver injury (DILI) in MS patients under pharmacological therapy. This observation could be a 
spurious phenomenon or could represent an actual new ADR. Pharmacovigilance studies, by 
including millions of data, allow to detect possible signals of new ADR during post marketing drug 
use in clinical practice.  
Objective: The main objectives in this thesis were to provide data on the possible role of 
drugs in MS development, as well as on safety profile of MS therapies. In details, we intended to 1) 
conduct a literature review of available evidence on the role of drugs in MS development and its 
worsening (part 1), 2) conduct a signal detection analysis to assess MS events during any drug 
treatments (part 2), 3) analyze signals of DILI events during MS therapies (part 3).  
Methods: For the first part, we screened scientific literature, by starting from an ad hoc 
search strategy in Medline and EmBase, with the terms “drugs exposure” and “MS 
onset/worsening”. Each included record was classified according to the phase of the disease 
(onset Vs worsening), type of study (case report, case series, case-control study, cohort study and 
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clinical trial) and drug under study. Relevant indicators were extracted as well as number of cases 
for longitudinal studies, whereas Naranjo algorithm was applied for case reports and case series. 
Finally, quality of studies was assessed by using proper scales according to the nature of the study 
(part 1 of this thesis).  
Then, FDA Adverse Event Reporting System (FAERS), a freely available database 
downloaded from the FDA website, was explored. After data management of the raw archive 
(q1_2004-q2_2016), case and non-cases were extracted. Case were represented by reports 
indicating “*Multiple Sclerosis*” as adverse event, whereas other ADRs were considered non-
cases. In order to decrease spurious signals, we excluded records in case of: 1) presence of MS 
drugs, 2) presence of vaccines, 3) presence of non-MS drugs with MS in the field “indication”. In 
order to increase the specificity of analysis an ad hoc index, named cleaning index, was developed 
by considering the proportion of records remained after application of exclusion criteria. A 
case/non-cases strategy of analysis was applied and reporting odds ratio (ROR) with relevant 
confidence interval (95%CI) was calculated. Signals were claimed when drugs presented at least 10 
cases, significant ROR (lower limit > 1) and cleaning index ≥70% (part two of this thesis).  
For the third part, we applied the above mentioned case/non-case strategy to analyze 
update archive (q1_2004-q4_2016). Cases were represented by records with at least one MS 
therapy and at least one preferred term (PT) suggesting a DILI event. Two definitions of DILI were 
considered: overall liver injury (OLI, broad definition) and severe liver injury (SLI, narrow 
definition) focused only on severe events. Then, ROR (95%CI) was calculated and signal was 
claimed when specific drug showed at least 3 cases with significant ROR. Finally, case-by-case 
analysis was performed, by detecting concomitant presence of drugs already associated with liver 
damage or specifically used to treat hepatitis.      
5 
 
Results: From analysis of literature several case reports and case series suggested a 
possible link between drug exposure and MS onset or its worsening, whereas longitudinal studies 
were few and sometime with contrasting results. Drugs acting on immune system were the most 
studied suggesting a link between their use and MS development, hormone balances and 
infections were also investigated but without homogeneous conclusions among different studies. 
However, the low quality was find in most studies, and the high frequency of missing information 
did not allow comparison of different findings.  
FAERS analysis showed signals for drugs acting on immune system such as etanercept, 
adalimumab, infliximab. Disproportionality signals were found also for contraceptives, insulin and 
bisphosphonates. Our advanced strategy of analysis actually allowed to exclude from the signals 
drugs generally used as symptomatic agents in MS, for instance baclofen and methylprednisolone.  
As for DILI events, interferons as well as mitoxantrone showed significant results. In fact 
according to previous publications they have been already classified as potentially hepatotoxic 
drugs. Signals were found also for alemtuzumab, teriflunomide and the symptomatic agent 
fampridine. Finally, case-by-case analysis showed concomitant presence of drugs potentially 
involved in liver damage and generally used to treat MS symptoms such as baclofen.  
Conclusions: In part 1 and 2 we highlighted that a possible role of drugs in MS 
pathogenesis cannot be completely excluded, especially for biologics, hormones and antifectives. 
They can represent cause per se of disease onset or proxy of concomitant/previous disease able to 
trigger MS onset.  
As regards MS therapies, in part 3 we found possible links between MS drugs exposure 
and subsequent DILI events. However, concomitant presence of other medications raises concerns 
on possible interactions with them that can trigger DILI events (e.g., gabapentin). We suggest 
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continue liver test during MS therapies in order to detect early enzymes abnormalities potentially 
involved in subsequent liver damage.  
 In conclusion, this thesis highlighted the importance of pharmacovigilance studies 
especially for rare and unpredictable ADRs. We encourage healthcare professionals and 
consumers to report as detailed as possible every ADRs to the relevant authority and to scientific 
community. This effort is crucial for better characterizing signals and for allowing to perform 
sensitivity analyses on specific groups of cases, in order to obtain useful information for future 
clinical and regulatory decisions. 
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ABBREVIATIONS 
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9 
 
PPMS Primary progressive multiple sclerosis 
PRMS Progressive relapsing multiple sclerosis  
PT Preferred term  
ROR Reporting odds ratio  
RRMS Relapsing remitting multiple sclerosis  
SLI Severe liver injury  
SMQ Standardized medDRA queries  
SNP Single nucleotide polymorphism  
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VCAM-1 Vascular cell adhesion molecule 1 
VDR Vitamin D receptor 
WHO World Health Organization 
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1. INTRODUCTION  
 
 1.1 Epidemiology of Multiple Sclerosis 
 
This year is the 180th anniversary of the first case of “Sclèrose en plaque dissèmonèes”  a 
disease currently known as Multiple Sclerosis (MS) (1). MS Generally affects 30 year or older 
individuals and only 2-5% of cases are diagnosed before 18 years old (2). MS has a complex 
pathological mechanism characterized by the contemporary presence of inflammatory and 
degenerative processes of central nervous system. It is well known that MS has a different 
incidence and prevalence worldwide (3, 4). A gradient can be identified from equator (less cases) 
to the northern regions (more cases, Figure 1.1a). In fact, Northern Europe, Northern America 
Southern Australia and New Zealand have higher prevalence of MS with over 30 cases per 100,000 
inhabitants; lower prevalence about 5-30 cases per 100,000 inhabitants is registered in Southern 
Europe, Southern USA and Northern Australia; whereas less than 5 cases per 100,000 inhabitants 
can be detected in Asia and South America (5). Of particular interest is the case of Sardinia, an 
island of Italy, that shows higher prevalence (more than 100 cases per 100,000 inhabitants) as 
compared to the rest of the Country (3), maybe due to population characteristics. This represents 
a case of isolated population with peculiar environmental characteristics as well as lower genetic 
variability due to scarce migration phenomenon. It should be mentioned that according to the last 
MS report, latitude effect seems to be less incisive than other risk factors if we focus on general 
MS incidence worldwide (6). 
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The number of new diagnosed people increased from 2.1 million in 2008 to 2.3 million in 
2013 (2). This can be justified by both improvements in diagnostic criteria and increased 
awareness of clinicians about early symptoms and clinical course of disease (7).  
For many decades clinicians have had several misconceptions about MS also because 
many aspects of disease were unclear. One of those was possible sex difference in MS risk (8). In 
the early 1900s clinicians though that MS was a typical male disease with ratio male:female 
distribution of 3:2. Then, National MS society updated this ratio to 1:1. Only in the last decades the 
incidence rate was updated to 2:3.6 (6). The initial misclassification of disease was due to gender 
stereotypes. In fact, in the past, women were considered more prone to suffer from hysteria and 
this fact contributed to underdiagnosis of the disease, whereas men, which were considered more 
Figure 1.1a. Prevalence of multiple sclerosis worldwide. The figure illustrates 
prevalence of MS across different part of the Earth with prevalence reported per 
100,000 inhabitans population. Reprint by permission from Elsevier: The Lancet 
Neurology 3: 710,19 © Copyright 2004. 
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important in the society, also for their power in workforce, received a proper diagnosis  (8). 
However, sex difference and latitude distribution do not represent hard risk factors of disease 
because also many other factors may have a role in this disease such as sun exposure, vitamin D 
level, infection and genetic variants (6).  
 
 1.2 General characteristics and pathogenesis of Multiple Sclerosis  
 
MS is an example of multifactorial disease that is influenced by environmental factors and 
genetic predispositions. While pathophysiological mechanisms are incompletely studied, its clinical 
manifestations is well documented.  
In this intricate scenario, four clinical phenotypes of MS can be individualized: relapsing 
remitting (RRMS), secondary progressive (SPMS), primary progressive (PPMS) and progressive 
relapsing (PRMS) (9). By the time, these variants of disease were grouped into two main 
representative phenotypes: relapsing and progressive disease (10). The RRMS represents the most 
diagnosed type of MS accounting for almost 85% of total diagnoses of MS. By a clinical point of 
view, typically the RRMS is characterized by relapses followed by recovery (partial or complete). In 
this context, the first episode of disease is called Clinically Isolated Syndrome (CIS) which is not 
enough to have a diagnosis of MS, because it does not fulfill the criteria of dissemination in time 
even if involved in inflammatory events (11). On the contrary, few evidence are available for 
progressive form that remains almost completely under-investigated. Progressive MS is generally 
characterized by gradual accumulation of damage without recovery; clinicians refer to PPMS when 
it represents the first diagnosis whereas SPMS when represents a worsening of RRMS (10). 
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 Migration of T- and B- lymphocytes in the Central nervous system (CNS) represents the 
crucial and first step to develop multiple sclerosis (12). However, the complete process has not 
been elucidated and many steps remain still unknown. Demyelination and neurodegeneration is 
generally associated with inflammation especially during relapse of disease (13, 14). Dysregulation 
of immune system due to intrinsic (e.g., cytokines receptors, microRNA) and extrinsic factors (e.g., 
regulatory T-cell dysfunction) affects T cell with consequent migration of them from peripheral 
areas into central nervous system (15). Impairment of T cells function leads also an indirect 
impairment of B cells with abnormal proliferation of these in the blood (16). These act against 
blood brain barrier (BBB) causing its increased permeability with subsequent infiltration of 
lymphocytes (17). In this phase of disease several mechanisms act simultaneously: production of 
immunoglobulin G and interleukin 6, activation of MHC class II-dependent antigen-presenting (18) 
resulting in demyelination of the CNS meanwhile production of metalloproteinase-9 destroys BBB 
(19).  
All the processes described above are heavy influenced by genetic and environmental risk 
factors (e.g. virus infection (20)).  
Knowledge of pathological mechanisms involved in MS disease allowed to create new 
therapies, albeit far to be considered as capable to resolve the disease, devoted to act on specific 
target in order to decrease severity of relapse.  
 
 1.3 Multiple Sclerosis and risk factors 
 
Multiple sclerosis is an autoimmune neurodegenerative disease. The pathological 
pathways involved in its onset and worsening are still far to be completely elucidated. However, 
some risk factors have been identified. Among those, the most plausible risk factors are: genetic 
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predispositions, which include mainly genetic variant that increase MS risk, and 
environmental/biologic factors that can be associated to the disease onset (i.e., vitamin D level 
and sun exposure, virus infections, smoking and obesity).  
 
1.3.1 Genetic variants 
 
Studies on genetic susceptibility indicate that MS risk increases with decreased of genetic 
distance. The risk to develop a new episode of MS is about 9.2 for individuals with MS cases 
among first-degree relatives, 3.4 among second-degree and 2.9 for those with third-degree (21). 
Additionally, MS risk seems to be 10 folds higher for children of conjugal with MS than single 
affected parent (22, 23). Differences can be detected also among sibling, in fact monozygotic twin 
have a risk roughly 24-30% compared to heterozygote with 3-5% (24, 25).  
In spite of evidence on possible association between genetic variants and MS risk, this 
disease is not considered a Mendelian disease because genetic variants represent only one of the 
several factors able to influence MS onset.  
Association between multiple sclerosis and Major histocompatibility complex (MHC) have 
been supposed since 1970 (26, 27). In particular, genetic modification in genes encoding for 
human leucocyte antigens (HLA) class II have been associated with increased risk to develop the 
disease: HLA-DR15, HLA-DR16 and HLA-DQ6 genes in general population and HLA-DR4 for Sardinia 
and Mediterranean populations (28). In addition, individuals with allele HLA-DRB1*15.01 variants 
seem to have higher risk to develop the disease than general population (29).  
Genome wide association studies have identified new genetic variants which may be 
associated with MS development (30, 31). These variants interest HLA-I and non-HLA loci (32, 33). 
Mutations in these loci are involved in alteration of structures and functions of receptors and their 
ligands. In particular, mutations of gene IL2RA and IL7RA are involved in interleukin 2 and 7 alpha 
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receptors modification; whereas STAT3, TNFRSF1A and TYK2 modifications encode for signal 
transducer and activator of transcription 3, tumor necrosis factor receptor 1 and tyrosine kinase 2 
enzyme alteration potentially involved in MS pathology.  
In spite of several genetic variants have been already associated with MS, influence of 
other ones cannot be completely excluded. It should be remembered that as happen for non 
Mendelian diseases, presence of one of these variants cannot represent cause per se of disease 
(34, 35). 
Lastly, epigenetic alterations such as histone modifications which are primary involved in 
myelination and degeneration pathways can influence disease development and its progression 
(36). More studies need to evaluate the role of genetic and epigenetic factors in MS pathogenesis 
taking into account also environmental factors able to influence both of them.   
  
1.3.2 Vitamin D level 
 
Vitamin D is a nutrient introduced into human body through two main routes: orally and 
by UV exposure (37, 38). Pre-vitamin D3 is naturally synthesized in the skin when UBV strikes the 
skin with consequent conversion of 7-dehydrocholesterol in pre-vitamin D3, which spreads into 
the body by using cardiovascular system (39). The oral intake of vitamin D is characterized by 
vitamin D2 (mainly from vegetables sources) and vitamin D3 (mainly from animal sources). In liver 
pre-vitamin D3 is converted in vitamin D3 and then in 25-hydroxyvitamin D (25(OH)D) (40). 
Ergocalciferol (vitamin D3) and colecalciferol (vitamin D2) after conversion in 25-hydroxyvitamin D 
can undergo a second hydroxylation in the kidney producing 1,25-dihydroxyvitamin D (called also 
calciferol see figure 1.3.2a) (41). Generally, 25-hydroxyvitamin D is used as marker of vitamin D 
concentration in the blood instead of vitamin D3 or 1,25-dihydroxyvitamin D because has long half-
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life and it is directly depending on vitamin D concentration but it is also less influenced by 
hormones than vitamin D metabolism (38, 40).   
 
 
 
 
After the first hypothesis of possible role of vitamin D in MS pathogenesis in 1974, many 
studies were conducted to assess the possible association between this nutrient, and in particular 
its deficiency, with multiple sclerosis onset (42). A nested case control study, including 148 cases 
and 296 controls, found a decreased risk to develop MS in individuals with higher level of 25-
hydroxyvitamin D. The study suggested that this inverse association is true only for white 
individuals because no significant results were found for Blacks and Hispanics (43). In 2012, Salzer 
and colleagues including roughly the same number of cases from Swedish population, identified an 
inverse association between 25(OH)D≥75nmol/L and MS risk (44). Another study explored the role 
of vitamin D instead of 25(OH)D (45). In this case, high concentration of vitamin D was associated 
Figure 1.3.2a. Metabolism of vitamin D. Figure illustrates Vitamin D metabolic pathway. Vitamin 
D from skin, animal and vegetable sources are converted in 25-hydroyvitamin D in the liver and 
then in its active form 1,25-dihydroxyvitamin D in the kidney less in other tissue.  
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with decreased risk to develop MS during follow-up. In addition, also vitamin D supplements (≥400 
UI/Day) was inversely associated with MS risk (45). In a multinational case-control study, self-
reported vitamin D supplements was associated with reduced MS risk (46). Also other studies with 
different methods to detect vitamin D intake were consistent with previous results (47-49). Finally, 
also a Mendelian randomization studies found an association between specific single nucleotide 
polymorphism (SNP) and MS. In particular these SNPs are correlated with vitamin D level and can 
be used in order to avoid generic confounders, almost impossible to control, that can affect study 
on vitamin D concentration such as sun exposure (50-52). 
Animal studies by using an experimental autoimmune encephalomyelitis (EAE), the mice 
model of MS, found that vitamin D and its metabolites have a protective role in disease onset and 
progression (53). Two mechanisms can be supposed, 1) 1,25-Dihydroxyvitamin D3 acting on Th1 
cells and activating macrophages inhibits their activity and blocks disease progression; 2) 
stimulation the proliferation of encephalitogenic cells (53). Other studies suggested that several 
pathways are involved in animal model, and hypothetically also in human, in protective effect of 
vitamin D including: IL-10 pathway (54), modulating Rag-1 dependent cell such as autoreactive T 
cell (55), and modulating the vitamin D receptor (VDR) on T cell surface (56). Furthermore, 
25(OH)D and 1,25(OH)2D seem to decrease Th17 cell differentiation (57, 58), same results were 
observed in MS patients (59).  
Vitamin D levels seem to influence also disease activity and progression. In fact, two 
longitudinal cohort studies found that high level of 25(OH)D was associated with decrease disease 
activity and slower progression, predicting lower disability during follow-up (60, 61). The role of 
vitamin D supplements during MS therapies is still debated (62). However, a trial found reduced 
MRI disease activity in patients treated with interferon beta and vitamin D (63).  
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Finally, considering the disease characteristics and the possible concomitant influence of 
other risk factors rather than mere vitamin D levels, further studies need to assess the role of this 
supplement in MS therapies.  
  
1.3.3 Epstein Barr virus infection 
 
Microbial infections have been suggested as possible cause implicate in MS development 
in susceptible individuals. However, these agents may also trigger MS development by accelerate 
subclinical autoimmune processes (64). Among the possible infections proposed as cause of MS 
development (bacterial and virus) only Epstein Barr virus (EBV) has been associated with increased 
MS risk (65).  
A prospective study among US military personnel, including 222 MS cases and 444 
matched controls, aimed to estimated MS risk among EBV positive individuals. MS risk was higher, 
36-fold, among individuals with anti-EBNA complex IgG titers above 320 compared with individuals 
with anti-EBNA titer lower than 20 (66). Further, another study aimed to detected possible link 
between several viruses (HBV, human herpes virus, herpes simplex virus, varicella zoster virus and 
measles) and MS risk. Among the analyzed virus only EBV had significant results suggesting a role 
in MS disease (67). A study published in 2010, included 305 MS cases and 610 matched controls, 
by using blood sample collected before MS onset had the purpose to establish possible temporally 
sequence between EBV infection and MS onset (68). Results from this study suggested that after 
seroconversion (individuals affected by EBV virus) the risk to develop MS increased if compared to 
people without seroconversion (individuals without EBV infection).   
The mechanisms implicated in MS development after EBV infection is still not completely 
understood. A possible hypothesis includes several dysregulations in immune system functions 
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due to virus infection (69). In particular, virus infection inhibits functional suppression at T-cell 
level, additionally EBV homing in B-cell contributes to the distinct characteristics of EBNA-specific T 
cell in MS subjects. Finally, after EBV infection neurons of central nervous system are more prone 
to induce immune response with consequent inflammatory processes due to EBV antigens on their 
surface (69). So, EBNA1-T cell are more prone to recognize myelin antigens inducing inflammatory 
response that is involved in CNS damage (70). Finally in these intricate pathways also genetic 
component can affect EBNA1-T cell selection and proliferation and therefore deserves further 
evaluations (70).   
 
1.3.4 Smoking 
 
Several studies have been conducted in order to explore association between smoking and 
multiple sclerosis. The first time that smoke can represent a risk factors for MS development was 
suggested in 1965, by using a case control study that found higher proportion of MS cases among 
smokers compared to controls (71). This find was in contrast with two studies conducted in United 
Kingdom, which were planned for other purposes and that found a non-significant association 
between smoking and MS development (72, 73).   
In 2002 a Canadian case-control study including 200 cases and 202 sex- and age-matched 
controls found an association between cigarette smoking and MS risk (74). Then, two large 
prospective cohort studies which included US female nurse confirmed previous results (75). Some 
years later, the same authors conducted a new nested case-control study with 201 cases and 
1,913 controls (76). They found an increased risk to develop MS (Odds ratio: 1.3; 95%CI: 1.0-1.7) in 
ever-smokers compared to never-smokers. Another study focused on relapse risk found increased 
risk to have a progression of disease (Hazard ratio: 3.6; 95%CI: 1.3-9.9) in MS smoker individuals. 
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In addition, cigarette smoking seems to lead a reduction of functional level in MS patients even if 
had a good EDSS score (77). A recent study has suggested that smoke is able to influence also 
therapeutic effects of MS treatments decreasing their efficacy and increasing probability to 
experience relapses during treatments (78).  
Association between smoke and increased MS risk have been supported by several studies 
conducted in Norway (79), England (76), Serbia (80), Sweden (81), Iran (82) and Australia (83).     
Finally, some meta-analyses have been conducted and updated in the last years and all of 
them agree on the role of smoke in MS development. Two of them, including 26 and 29 studies 
concluded that smoker men are more susceptible than women to develop the disease (OR: 2.14; 
95%Cl: 1.80-2.55) (84, 85), and current smokers are more prone to develop MS than past smokers 
(OR: 1.83; 95%Cl: 1.42-2.37) (84, 86). 
The complete mechanisms cause of MS development or its worsening are far to be 
completely elucidated. Smoking cigarette can affect other inflammatory response, immune system 
activity as well as epigenetic pathways (87, 88). Free radicals and in particular hydrogen cyanide 
are produced during cigarette combustion. Basic research showed that this compound is 
responsible of demyelinating processes in central nervous system (89, 90). Oxidants can cause 
alteration of B and T cells through alterations of cell membrane functions increasing number of 
pro-inflammatory agents (91-93). Smoking can affect also gene expression through epigenetic 
pathways. An increased risk of MS was observed in individuals with HLA genes alterations. The 
most studied genes are HLA-DRB*1501 and HLA-A*0201 only for Nordic individuals (94-96). In this 
intricate scenario, further studies need to elucidate the role of environmental and genetic factors 
interplay in MS development.   
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1.3.4 Obesity 
 
Several studies investigated the role of body mass index (BMI) in MS pathogenesis (97-
103). Two studies setted in Nurse home called Nurse’s Health I study (121700) and Nurse’s Health 
II (116671) by using cox regression model found that obesity (BMI≥30 Kg/m2) at age 18 was 
associated with higher risk to develop MS (102). A Danish study that included individuals who 
were born in the early 20th century suggested that those were more prone to develop MS if they 
had higher BMI at age 7 to 13 (101). 
Case control studies carried out in Norway, Italy, Sweden and US including about 3,000 MS 
cases and much more controls showed an increased risk to develop MS for individuals with higher 
BMI during childhood and adolescence (98-100). 
The biologic mechanisms involved in the observed phenomenon are still far to be 
completely elucidated, even if also vitamin D can be involved. The main hypothesis supports an 
interplay between vitamin D level in obese individuals and MS development. In fact, a meta-
analysis found an inverse association between vitamin D level and BMI (104), this can be due to: 1) 
scarce sun exposure due to impaired mobility of obesity people; 2) change in vitamin D 
metabolism in liver and bones; 3) over storage of vitamin D in the body fat (104-106). Obesity is 
associated also with inflammatory processes that can increase MS susceptibility (107). Adipocytes 
produce several pro-inflammatory cytokines such as IL-6, tumor necrosis factors and leptin able to 
induce alteration in immune system functions with consequent triggering of MS development 
(108, 109). 
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 1.4 Therapeutic armamentarium for Multiple Sclerosis  
 
Management of multiple sclerosis is challenging for clinicians and patients, which currently 
deal within an increasing number of therapeutic alternatives (110). Nowadays, therapeutic 
strategy is focused on the reduction of the risk of relapses and disability progression after MS 
diagnosis (110). The uncomplete knowledge of pathophysiological mechanisms of MS onset and its 
worsening increased the needs to develop drugs able to target different pathways. So far, 11 drugs 
(included in this thesis) plus two new molecules (not included in this thesis because approved only 
recently) have been authorized for MS treatment. In MS therapies, 3 milestones can be reminded: 
first authorized therapy in 1995, first monoclonal antibody specifically addressed to MS in 2005 
and first oral treatment in 2011 (Figure 1.4a).  
 
 
Figure 1.4a. Time sequence of approved MS therapies. The figure illustrates the 
chronological sequence of available drugs; in violet injectable therapies, in orange oral ones 
and in green injectable and monoclonal antibodies therapies.  
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The huge heterogeneity of available therapeutic armamentarium makes almost impossible 
to prioritize treatment options, so usually interferons were considered the first choice followed by 
another option in case of scarce risk-benefit profile and according to the patient characteristics 
(10). However, a sort of categorization based on the clinical effect can be proposed: 1) therapies 
with moderate efficacy or indicated for initial treatment of disease such as interferon beta 1a, 
interferon beta 1b, glatiramer acetate, fingolimod, teriflunomide and dimethyl fumarate; 2) high 
efficacy or indicated in later disease modifying therapies such as mitoxantrone, natalizumab, 
alemtuzumab and daclizumab (recently withdrawn from the market); and 3) symptomatic therapy 
such as fampridine.  
 
1.4.1 Moderate efficacy or standard initial treatment 
 
Moderate efficacy or standard treatment category includes the first used option therapy, 
interferons, and part of the second line treatments: glatiramer acetate, fingolimod, terifluonimide 
and dimethyl fumarate.  
These substances represent a heterogeneous group of drugs with different route of 
administration (e.g., injectable and oral), scheme of therapy, doses and mechanisms of action.  
In the following sections the most important characteristics of each included therapy will 
be briefly described. 
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1.4.1.1 Interferons beta 
 
Interferons are the first drugs specifically authorized for MS treatment. Firstly, was 
Interferon beta 1b called Betaseron® authorized in 1993, subsequently, other three drugs were 
approved with the same indication: two formulations containing interferon beta 1a (Anovex® and 
Rebif®) in 1997 and 2000 respectively, and its pegylated form marketed as Plegridy® in 2014 (111-
114).  
Although the exact mechanism of action is still unknown, different possible mechanisms of 
action have been proposed for their therapeutic effects. Among those, the mains are: suppression 
of cells functions and reduction of interferon gamma secretion by activated lymphocytes; 
activation of macrophage; and downregulation of class II MHC induced by interferon gamma with 
consequent reduction of antigen-presenting glial cells (115). Additionally, interferons beta 
suppress T cell proliferation, increases natural killer production and decreases blood brain barrier 
(BBB) permeability by reducing activity of metalloproteinases (116, 117).  
Interferons beta have the longer period on market and many data are available on their 
safety profile. Usually, treatment with these drugs is associated with flu-like symptoms, local 
injection-site reactions, lymphopenia, complex headache and pain (118). In addition, adverse 
events associated with self-injection are cause of drug discontinuation in a range between 14% 
and 44% of treated patients with consequent relapse of disease (119). However, self-injectable 
devices improved compliance to this therapy (120) decreasing most of uncomfortable aspects 
associated with self-administration. However, the most dangerous adverse effect is represented 
by liver damage associated with their use (121). In fact, liver damage ranged from mild and 
moderate enzyme elevation, generally resolved with drug discontinuation, to acute hepatic failure. 
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Liver enzymes monitoring and drug discontinuation are recommended in case of abnormalities 
during ongoing treatment (121).  
In spite of adverse effects associated with interferons use, usually, they are considered 
and used as first line of treatment for both first symptoms and relapses. However, a recent meta-
analysis including all authorized therapies for MS treatment reveal unclear results on real benefit 
of early treatment with interferons compared to other therapies (122).  
 
1.4.1.2 Glatiramer acetate  
 
Glatiramer acetate (GA) was discovered in 1970 (123), but only in 2001 Copaxone®, the 
brand name of active substance GA, was approved by FDA (124). Glatiramer acetate is a mixture of 
polypeptides randomly polymerised from four amino acids: L-glutamic acid, L-alanine, L-tyrosine 
and L-lysine (124, 125). The mechanism of action of this drug has still been incompletely 
understood. However, some proprieties are well known. Firstly, it binds major histocompatibility 
(MHC) class II molecules, preventing the presentation of other antigens and reducing T-cell 
activation. GA acts on monocytes and dendritic cells with consequent inhibition of first cells and 
less production of TNF-alpha, IL-12 and increased production of IL-10 by the second ones (126). 
Animal studies suggested also a neurotrophic effect of GA in murine model. In fact,  neurotrophic 
factors such as production of BDNF and neutrophin 3 and 4 were detected in peripheral and 
central nervous system of animals after treatment (126).  
Usually, a dose of 20 mg/mL per day is well tolerated by patients and according to the 
clinical trials the most reported adverse events are injection-site reaction as well as vasodilatation, 
dyspnea, depression, tachycardia, dizziness and tremor (124, 127). 
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In conclusion, glatiramer acetate acting on different levels on immune system activity 
results in a general anti-inflammatory and neuroprotective response with consequent benefits of 
treated individuals (126, 128). 
 
1.4.1.3 Dimethyl fumarate 
 
Dymethyl fumarate (DMF) is an oral therapy included in MS armamentarium by FDA in 
2013 and marketed as capsules of both 120mg and 240 mg dose (129). 
This agent is a derivate of fumaric acid, a metabolite of Krebs cycle, that claims anti-
inflammatory, cytoprotective and immunomodulating functions (130-132). The complete 
mechanism of action of this drug is far to be completely elucidated, however, some lines of 
evidence are available from molecular and animal studies. In fact, DMF is responsible of activation 
of nuclear factor (erythroid-derived 2)-like 2 (Nrf2) transcriptional pathway (129, 132, 133). In vitro 
studies highlighted that DMF (129) induced anti-oxidative pathways by regulating Nrf2 (132, 133). 
In particular, monomethyl fumarate (an active metabolite of DMF) was able to stabilize and 
translocate Nrf2 in the nucleus (133). This step increases production of anti-oxidative enzymes 
resulting in major concentration of oxygen species scavenger (130-133). Finally, these agents (DMF 
and its metabolites) seem to decrease also oxidative stress in astrocytes and neurons (132, 133).  
Animal studies pointed out beneficial effects of DMF in murine model of MS (133, 134) by 
decreasing inflammatory infiltrate and increasing anti-inflammatory cytokine (e.g. interleukin-10). 
In addition to the Nrf2 effects, this agent inhibits also expression of inflammatory cytokines, 
chemokines and adhesion molecules due to nucleus translocation block of factor-kb (135).  
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Finally, DMT showed apoptotic effects on human T cell (136, 137) and this may be 
responsible of depletion of circulating lymphocytes during DMT treatment.  
The most reported adverse effect associated with DMT use are: nausea, diarrhea 
abdominal pain and flushing (129). As regards flushing this may be caused by monomethyl 
fumarate bindings with nicotinic receptor that cause PGE2 formation via GPR109A and COX-2 
pathways (138).  
Even if the exactly mechanisms of action of DMT deserve more evaluations, this drug 
seems well tolerated by patients (139). In addition, its route of administration can be a factor that 
may increase also adherence to the treatment.  
 
1.4.1.4 Fingolimod 
 
Fingolimod was approved by FDA in 2010 and marketed with brand name Gylenia ® (140). 
It has been authorized as single agent in MS disease and it is able to reduce both clinical 
exacerbation of disease and accumulation of physical disability (141). 
Fingolimod is an analogue of sphingosine and acts as antagonist of sphingosine 1-
phosphatase receptors (S1PRs) except S1PR2. The S1PRs are largely expressed on surface of many 
types of cells and are involved in several cell pathways: differentiation, survival, movement, 
angiogenesis, inflammation and immunity (142). This drug regulates traffic of T- and B- cells across 
lymphoid tissues, bone marrow and circulatory system. In particular, once fingolimod binds its 
receptors on the lymphocytes surface inhibits their egression from thymus and lymph nodes with 
consequent reduction of circulating lymphocytes (143). Further, fingolimod is able also to reduce 
humoral response and interferes with degenerative process in the brain and spinal cord (141).  
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Among treated patients hyperpolarization of atrial myocytes resulting in reduction of heart 
rate and reduction of pulmonary function were observed (144, 145). Both of the above ADRs are 
consequences of its effect on S1PR receptors of cardiac and pulmonary cells. Finally, this agent has 
been associated with cystoid macula oedema (140, 146). Considering the pharmacologic effect on 
cardiac and pulmonary cells co-administration of fingolimod with other drugs with similar effects 
such as β-adrenergic receptor antagonists (e.g. atenolol), class Ia and IIa of antiarrhythmic, calcium 
channel blockers (e.g. dialtiazem), digoxin, anticholinesterase inhibitors (e.g., neostigmine) and 
pilocarpine should be avoided (140, 144, 147). Regulators suggest no vaccination with attenuated 
virus during treatment and in the following two months after drug discontinuation because of high 
risk of infection; as this regards continuous monitoring of patients for possible opportunistic 
infections are suggested (140, 147). 
In spite of mentioned risks benefit of this therapy was highlighted also in a recent 
publication that suggested lower rate of switch from first treatment to another one for those 
firstly treated with fingolimod (148). However, it should be recognized that several aspects can 
influence the first treatment choice (i.e., disease activity, time gap between first symptoms and 
final diagnosis and age) and all of them have a role also in adherence to the treatment.  
 
1.4.1.5 Teriflunomide 
 
Teriflunomide, marketed with brand name Aubagio®, was approved by FDA in 2012 (149). 
The main mechanism of action involves inhibition of lymphocytes proliferation by blocking these 
cells in S phase of mitotic division. Teriflunomide blocks production of de novo synthesis of 
pyrimidine by reversible inhibition of dihidro-orate dehydrogenase (DHODH) enzyme in the 
mitochondrial and highly expressed in proliferating lymphocytes (150). As result of above activity, 
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a general cytostatic effect on proliferating T- and B-lymphocytes were obtained, with consequent 
reduction of disease activity (151).  
This agent was the second drug, licensed for MS treatment after interferons, and it is able 
to reduce disease activity during acute phase (152). In clinical trials teriflunomide showed a good 
risk benefit profile having moderate adverse events (≥2% of treated individuals) such as alopecia, 
headache, diarrhea and hypertension (152).  
By pharmacological point of view, teriflunomide is a metabolite of leflunomide used to 
treat rheumatoid arthritis (153). This last agent has already been associated with hepatic failure, 
therefore as precautionary measure FDA recommend periodic hepatic enzymes tests also in new 
treated patients with teriflunomide (149).  
Finally, it should be noted that teriflunomide represents the first oral therapy available for 
MS patients. This is a crucial aspect that should be taken into account during treatment choice for 
patients. In fact, is easy to suppose that patients should be more confident with oral therapies 
rather than injectable ones and this can also contribute to their adherence to the treatment.  
 
1.4.2 High efficacy or later disease modifying therapies 
 
These agents are usually used as second- or third- line of treatment and include 
mitoxantrone and monoclonal antibodies. A recent network meta-analysis, by analyzing 33 studies 
among all the authorized MS therapies, showed that alemtuzumab, natalizumab and the recent 
approved drug ocrelizumab presented high efficacy in MS patients compared with other MS 
therapies (154). In the next section, we briefly describe pharmacological characteristics of these 
agents as well as those of mitoxantrone.  
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1.4.2.1 Mitoxantrone 
 
Mitoxantrone (marketed as Novantrone ®) was approved for multiple sclerosis treatment 
by the FDA in 2000 (155, 156). It is an anti-neoplastic anthracednedione derivate (157), targets 
topoisomerase II interfering with DNA repair as well as inhibiting DNA replication and RNA 
synthesis by producing crosslinking and single- double- strand breaks (157). These mechanisms 
involve in apoptotic processes resulting in inhibition of T- and B- lymphocytes cell proliferation 
(157, 158). Another possible mechanism of action could be represented by decreasing secretion of 
pro-inflammatory cytokines (157). 
A recent Cochrane meta-analysis confirmed the clinical efficacy of mitoxantrone on 
disease progression in MS patients (159). The most frequent adverse effects reported during 
clinical trials were: nausea, vomiting, alopecia and urinary tract infections (159). However, use of 
this drug seems to be associated with increased risk to develop acute myelocytic leukemia (AML) 
suggesting a careful evaluation of leukocytes blood levels before new cicle with mitoxantrone 
(159).  As regards cardiotoxicity induced by long treatment with mitoxantrone, this can be reduced 
by performing specific tests (i.e, electrocardiogram and echocardiography) in all potential 
candidate for this therapy (155, 159).  As see above for interferons, also during mitoxantrone 
treatment transient ALT elevation can occur due to toxicity of drug (121). Therefore, periodically 
monitoring of aminotransferase levels is recommended and therapy with this agents should be 
avoided in patients experienced hepatic failure (121, 155).  
Finally, a post marketing French study, by including a large population, found positive 
impact of mitoxantrone into long-term period of treatment (160). However, longitudinal base 
registry study RENEW (Registry to evaluate Novantrone Effects in Worsening Multiple Sclerosis 
Study) highlighted the importance to made a carefully evaluation of patients before new 
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treatment in order to reduce the risk of ADRs  (i.e., cardiotoxicity) associated with this therapy in 
peculiar sub-group of patients (i.e., first line therapy non responders) (161).   
 
1.4.2.2 Natalizumab 
 
Natalizumab represents the first monoclonal antibody specifically developed for MS 
treatment. It was authorized by FDA and marketed worldwide in 2004 with brand name Tysabri® 
(162). 
The mechanism of action of natalizumab is not yet completely elucidated. Natalizumab 
acts by blocking migration of T lymphocytes through the blood-brain barrier (BBB). In particular, 
this antibody binds α4 subunit of α4β1 and α4β7 integrins expressed on surface of lymphocytes. 
This action prevents possible binding with their receptors which include vascular cell adhesion 
molecule 1 (VCAM-1) expressed on vascular endothelial cells, osteopontin, fibronectin, and 
connectin segment-1 (CS-1) expressed in parenchymal cells (162, 163). A treatment with 300 mg of 
natalizumab via infusion is able to inhibit lymphocytes migration in the central nervous system 
with consequent reduction of disease activity (162, 163).   
The most common side effect is acute infusion reaction, but probably the most known 
ADR associated with natalizumab treatment is the development of progressive multifocal 
leukoencephalopathy (PML) a severe and sometime fatal complication (164). The PML is a 
demyelinating disease firstly detected in HIV patients and other immunocompromised patients 
(165). This disease interests the central nervous system (CNS) due to reactivation of polyomavirus 
JC (JCV) (164, 165). Clinically, patients who experienced PML have neurological deficit caused by 
lesions in the white matter of CNS that appear as demyelinated areas with infected 
oligodendrocytes located at the periphery (165).  
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 Nowadays, several improvements have been made for PML prevention and management. 
So far, three risk factors have been associated with PML development: 1) positive serostatus for 
anti-JCV antibodies; 2) prior treatments with immunosuppressant drugs; 3) use of natalizumab for 
more than 2 years (166-169). Severity of PML was a critical issue in clinical practice that raised 
concern among regulatory agencies. For this reason natalizumab had been temporarily suspended 
from the market until 2006 when after carefully evaluation of PML cases it obtained again 
authorization for MS treatment with some guidelines in order to decrease this risk in treated 
patients (170-172). 
 In spite of possible occurrence of severe PML, natalizumab has been representing a great 
therapeutic option for MS patients. Analysis of JCV antibody for possible natalizumab candidate 
patients, continuing monitoring during and after treatment discontinuation could lead to detect 
early PML onset contributing to improve patients’ management (169). 
Natalizumab could be considered a sort of milestone in MS therapy history. In fact, the positive 
results observed during clinical practice contributed to increase studies on new antibodies which 
are currently approved for MS treatment such as alemtuzumab and ocrelizumab (recently 
approved but not included in this thesis).  
  
1.4.2.3 Alemtuzumab 
 
Alemtuzumab was authorized for the treatment of B-cell chronic lymphocytic leukemia in 
2001 (173), and then as MS treatment in 2013 with brand name Lemtrada® (174). It is a 
humanized monoclonal antibody IgG1 against the CD52 protein, glycosylphosphatidylinositol 
(GPI)-anchored protein, expressed on surface of T (CD3+, CD4+ or CD8+) and B (CD19+) lymphocytes 
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and less on surface of other circulating cells (i.e., monocytes, macrophages and eosinophil 
granulocytes) (175, 176). The complete mechanism of action is far to be understood, because 
many aspects and roles of antibody and its targets are still under-investigate. The bond between 
antibody and its receptor cause cellular cytolysis and complement-mediated lysis involved in 
depletion and repopulation of lymphocytes (176). This is the most accredited theory on 
mechanism of action of alemtuzumab involved in immunity cells remodeling resulting in reduction 
of inflammatory processes (175, 176).  
Treatment scheme consists in 12 mg/day on 5 consecutive days following by infusion of 12 
mg/day for 3 consecutive days after 1 year from the first infusion (174). The most common side 
effect is infusion reaction generally resolved with methylprednisolone or other symptomatic drugs 
(177). Treatment with alemtuzumab is also associated with severe adverse events (177, 178). In 
fact, severe and sometime fatal autoimmune disorders (i.e. autoimmune thyroid disease), 
idiopathic thrombocytopenic purpura, goodpasture syndrome, and in a minority of cases thyroid 
cancer were reported (174, 177, 178).    
Apparently patients treated with alemtuzumab do not experience infections such as PML  
a typical complication of natalizumab that have been raised concern on its use in previous years. 
However, monitoring of individuals cured with this agent should be advocated in order to detect 
early ADRs associated with its use.  
 
1.4.2.4 Daclizumab 
 
Daclizumab is a humanized IgG1 monoclonal antibody binds the alpha subunit (CD25) of 
the human interleukin-2 receptor expressed on activated lymphocytes. The complete pathway of 
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action is still under-investigate, but the main effect of this antibody consists in general inhibition of 
lymphocytes activity in MS patients (179).  
This drug represents a paradigmatic example of agent already used as efficient therapy in 
organ transplanted patients (180), but extremely dangerous if used for different pathological 
condition (179). It was authorized as MS therapeutic option in summer 2016 with brand name 
Zimbryta® (179). However, after few months EMA’s Pharmacovigilance Risk Assessment 
Committee (PRAC) restricted its use only for patients with no benefits from other MS therapies 
because of some reports of elevation of hepatic transaminase enzymes and liver injury (181). 
Then, the pharmaceutical company owner of daclizumab voluntary withdrawn it from the market 
after seven cases of encephalitis and meningoencephalitis involved in MS treated patients (181).  
Nowadays, daclizumab does not represent anymore a valid therapeutic option for MS 
patients, but it is still included in this thesis because on the market when data on safety profile of 
MS therapies were analyzed.   
 
 1.4.3 Symptomatic therapy 
 
Multiple sclerosis patients during early phase of disease as well as relapse experience a 
widely number of symptoms. Neurologists and other specialists manage these symptoms by using 
a wide range of pharmacological and non-pharmacological options in combination with disease 
modified treatments (DMTs). Pharmacological treatments include steroids during phase acute of 
disease (i.e., 0.5 g daily for 5 days of methylprednisolone), amantadine for fatigue, baclofen and 
gabapentin (or combination of these drugs) for spasticity, gabapentin (as first choice) and 
memantine (as second one) for oscillopsia and other drugs for minor symptoms (182). 
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 Among all the therapeutic options used for MS symptoms, only fampridine was 
specifically approved as symptomatic agent for MS disease (183). In the next section we focus on 
this drug providing some pharmacological details.  
 
1.4.3.1 Fampridine 
 
Fampridine, also called dalphampridine, was approved by the FDA and marketed with 
brand name Ampyra®, as symptomatic drug for multiple sclerosis patients in 2010 (183). 
Fampridine is a broad inhibitor of K+ channels present on the surface of axons (184). The 
mechanism of action is far to be completely understood. The most accredited hypothesis suggests 
its role in prolonging of action potential in damaged neurons (185), and new data indicates also 
possible stimulation of N- and L- calcium channels (186). All of these mechanisms can reinforce 
synaptic transmission and increase muscle twitch tension, resulting in improving walking speed in 
treated individuals (184). 
It should be note that this agent does not have any effect on MS pathology, but can be 
used to improve walk impairments and to decrease fatigue in these patients (184). Fampridine 
seems to have a relatively safe profile, no drug-drug interactions were detected during clinical 
trials and the most common side effects were urinary tract infections, insomnia, dizziness, 
headache and balance disorders. For this reasons moderate use is recommended in patients with 
past history of convulsions, kidney failure and concomitant use of medication for seizure (184, 
187).   
Further studies could elucidate the effects of this therapy when administered together 
with other MS therapies in patients experienced first symptoms of disease and during relapses. 
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However, it should be remarked that it remain the first therapy specifically devoted to treat MS 
symptoms, that could be used as model for future therapies.  
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2. STUDY RATIONALE AND OBJECTIVE 
 
2.1 Rationale 
 
Several environmental and genetic risk factors have been already associated with MS 
development and its progression. However, the role of other potential risk factors cannot be 
excluded, as for example drug exposure. Data on drug exposure and new MS events can provide 
new insights on MS pathological pathways, also in light of concomitant diseases traceable by using 
drugs.  
 
On the other hand, the safety profile of MS drugs raises concerns among clinicians, 
patients and regulators. Several new drugs have been approved by EMA and FDA in the last 
decades, although data on their safety profile were still very scarce. For this reason, 
pharmacovigilance studies by using large databases are crucial in order to better define the side 
effects, especially by detecting rare ADRs, that were not properly addressed in clinical trials. This 
study phase is extremely important because of consequences in regulatory actions (restriction or 
withdrawn of drug) as well as in clinical management of the disease.  
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 2.2 Objectives 
 
The objectives of the present thesis are the following:  
1) Identify and evaluating the strength of evidence on drug exposure and multiple sclerosis 
onset and worsening, by developing an evidence mapping review of available findings in the 
literature.  
2) Providing new insights on signals of disproportionality for MS development after drug 
exposure, by analyzing FDA Adverse Event Reporting System database (FAERS).  
3) Providing  new insights on signals of possible association between exposure to drugs for MS 
treatment and drug induced liver injury (DILI), by analyzing the FAERS database.  
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3. METHODS 
 
3.1 Part 1: Evidence mapping of the literature 
 
3.1.1 Study design 
 
Since relationship between drug exposure and MS onset (or its worsening) is still debated 
we performed a literature review of available data. First, we defined a specific search strategy 
including terms “Multiple sclerosis” and “drug exposure” that was applied in two different 
databases: Medline and EmBASE.  
After merging records originated from the two sources and removal of duplicates, 
snowballing of reviews was performed in order to include additional relevant articles. Full texts of 
eligible articles were downloaded and analyzed, then each article was classified according to: 1) 
type of drug(s) included in the study, 2) type of study (clinical trials, cohort study, case-control 
study, case reports and case studies), and 3) stage of disease (onset, worsening).  
 
3.1.2 Causality and quality assessment 
 
For each included study the appropriate index summarizing the results was retrieved. In 
particular, odds ratio, relative risk, hazard ratio were selected for longitudinal studies, whereas 
Naranjo algorithm was performed for case reports and case series; all these data were included in 
the analysis (188). Type of association was classified according to above listed index as follows: 
positive (↑ increased risk), negative (↓ decreased risk) and no association (↔ if no effect was 
suggested).  
42 
 
As final steps, an analysis of quality of included studies was performed by applying 
appropriate scale: we used the Newcastle Ottawa scale for longitudinal studies (cohort and case-
control studies), whereas for case reports and case series the assessment was based on 
International Society for Pharmacoepidemiology (ISPE) and International Society of 
Pharmacovigilance (ISoP) guidelines (189). RTCs were excluded from this analysis because 1) no 
clinical trials are usually designed to study onset or worsening of new disease and 2) MS is rarely 
detected as adverse event in these studies due to its characteristics (i.e., long latency and still 
scarces awareness on drug-related component).  
 
3.2 Part 2 and 3: Analysis of FAERS database 
3.2.1 Data source: Food and Drug Administration Adverse Event Reporting 
System (FAERS) 
For the analyses included in studies 2 and 3, the FDA Adverse Event Reporting System 
(FAERS) was used. This database is one of the three large freely-available data source created by 
FDA for pharmacovigilance purpose: FAERS for drugs, VAERS for vaccine and CAERS for both food 
supplements and herbal remedies. 
FAERS is maintained by the FDA and represents the most suitable source of data to 
conduct pharmacovigilance studies. In fact, it collects reports from United State of America (USA) 
and severe ADRs from other regions of the World as for example from Eudravigilance maintained 
by European Medicines Agency-EMA, and Vigibase, by Uppsala Monitoring Centre of WHO, which 
include European and worldwide ADRs. This organization of data sharing makes impossible to 
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collapse the three sources of data in a unique database due to a large amount of overlapping 
reports.  
The FAERS is an open-source database that include anonymous data, for this reason 
ethical committee authorization is not request. Data are available on dedicated page of FDA 
website (190), and can be downloaded periodically in 4 quarterlies per years (Q1 including data 
from January  to March, Q2 from April to June, Q3 from July to September and Q4 from October to 
December). As shown in figure 3.2.1a this database consists of several datasets linked each other 
by specific Keys.  
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The entire database provides information on demographic characteristics, drug therapies 
and adverse events for each case. As mentioned above, each dataset is linked with relevant ones 
through specific keys (i.e., “primary-id” to identify the cases, “drug_seq” for drug information, 
“preferred term” for indication and adverse event). The same keys are used by researches to link 
Figure 3.2.1a. Food and Drug administration adverse event reporting system (FAERS) database 
complete structure for pharmacovigilance analysis. Figure illustrates FAERs database structure 
with particular focus on link among different dataset.  
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database information with external tools, which allow to codify data and to perform aggregated 
analyses (see next section for details).   
Here below, we detailed the main data generally used in pharmacovigilance studies:  
 Demographic data. This information are available in “Demographic” datasets and 
included data on sex, age, country and date of reported adverse event.  
 Drug data. These data are essential for the analysis and as shown in table 3.2.1a, 
they are linked to “Therapy” and “Indication” datasets (these last datasets are 
actually used only in some studies because of a higher rate of missing data). 
Information on drugs (brand name or substance name), dose, dechallenge (it 
indicates if symptoms were improved after drug discontinuation) and rechallenge 
(it indicates if symptoms reappear after drugs re-administration) are available 
with variable completeness. Crucial importance has information on the role of 
drugs, as defined by the reporter: in pharmacovigilance analyses, “primary” and 
“secondary suspected” drugs are usually taken into account, whereas 
“concomitant” and “interacting” drugs are preferably used as covariates for 
adjusted analyses. A rigorous datamining approach is needed before using these 
data, since drug name is a free text variable and misspelling errors can occur. 
From “Therapy” dataset is possible to retrieve data on date of start and end of 
therapy, whereas “indication” dataset provides information on reason for drug 
use. This last information is codified by using MedDRA dictionary.  
 Adverse Event data. “Reaction”, “Outcome” and “Report” source datasets contain 
the following information: the first two datasets include data on the specific 
observed ADRs (codified by PTs - preferred terms – of the MedDRA dictionary) 
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and their consequences (e.g., death, hospitalization, other), whereas the third one 
indicates the reporter of the case (i.e., physician, lawyer, customer, others). 
 Use of MedDRA dictionary and ATC dictionary (described in the next sections) allow to 
codify data available in the database and to conduct aggregate analysis on specific class of drugs or 
ADRs associated with specific organ/system classes of ADRs.  
 
3.2.1.1 ATC classification  
 
The ATC code is an alphanumeric code developed by the World Health Organization 
(WHO) (191) to harmonize the identification of medicines in the world. As shown in Figure 3.2.1a 
this code is included in a separate dictionary that is linked with FAERS through substance name.  
The code characterizes the authorized and commercialized drugs or combination of them. 
It is an hierarchical system based on anatomical, pharmacological, therapeutic and chemical 
characteristics of drug. It should be take into account that drugs used in different therapeutic 
areas are characterized by different ATC codes (e.g., acetylsalicylic acid, ATC code: A01AD05, 
B01AC06, N02BA01, M01BA03, N02BA51, B01AC56 and N02BA71), whereas unique ATC can 
identify different administration routes.   
The ATC code is characterized by 5 levels: 1st level consider the anatomical group, 2nd the 
therapeutic subgroup, 3rd the pharmacological subgroup, 4th the chemical subgroup and 5th the 
chemical substance (Figure 3.2.1.1a).  
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Figure 3.2.1.1a. ATC classification of drugs. In the figure is shown an example of classification 
from first to last level (Natalizumab; ATC code: L04AA23). 
 
In pharmacovigilance studies, codifying each substance in relevant ATC code is crucial in 
order to perform aggregate analyses. In selected research questions, substance name can be used 
when ATC code is not yet available.    
 
3.2.1.2 MedDRA dictionary 
 
Medical dictionary for regulatory activities (MedDRA) is a hierarchical classification of 
medical terms for pharmacovigilance and regulatory affairs (192). The structure of classification 
includes 5 levels, from the most general level, System Organ Class (SOC), to the most specific level 
named Preferred Terms (PTs) and its shadows lowest level term (LLT). This dictionary is linked with 
FAERS by using PT level, and it is used to codify both indications and adverse reactions. In MedDRA 
classification, a single PT can belong to more than one SOC (among which one is considered the 
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Primary SOC). Generally in pharmacovigilance studies Primary SOC is considered, because more 
specific (Figure 3.2.1.2a). Aggregate analysis can be made by using selection of PTs that can be 
already available in Standardized MedDRA Queries (SMQ). This approach is more appropriate to 
study complex ADRs (e.i., Drug induce liver injury).  
 
 
 
 
 
Figure 3.2.1.2a. MedDRA classification of medical terms. Figure illustrates classification of 
PT Multiple Sclerosis.  
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3.2.2 Statistical analysis of part 2 and 3 
 
3.2.2.1 Part 2: Multiple sclerosis drug induced 
 
For this study we downloaded FAERS quartiles from 2004 to first semester of 2016. After 
datamining of raw data (removing duplicated and records presenting 3 out of 4 identical content in 
sex, age, country, drugs and adverse event fields), drugs and adverse events were codified as 
previously described.  
According to the purpose of this thesis (detecting signal of drug-induced MS), we selected 
all cases that include as adverse event the terms “*multiple Sclerosis*”; the rest of records in 
database were considered as non-cases. In order to increase the specificity of analysis, we applied 
the following exclusion criteria to each record: 1) presence of drugs approved for MS treatment 
(e.g. interferons beta, mitoxantrone, teriflunomide, glatiramer acetate, fingolimod and 
natalizumab); 2) presence of drugs reporting “multiple sclerosis” as indication of therapy in the 
database; 3) presence of vaccines, because data on these entities are more specifically collected in 
a dedicated database (VAERS). Then, we developed an additional indicator named “Cleaning 
index” that represents the ratio between number of final records and number of initial records 
(before application of exclusion criteria; see formula 1): 
𝐶𝑙𝑒𝑎𝑛𝑖𝑛𝑔 𝑖𝑛𝑑𝑒𝑥 =
𝐹𝑖𝑛𝑎𝑙 𝑐𝑎𝑠𝑒𝑠 (𝑎𝑓𝑡𝑒𝑟 𝑒𝑥𝑐𝑙𝑢𝑠𝑖𝑜𝑛 𝑐𝑟𝑖𝑡𝑒𝑟𝑖𝑎)
𝐼𝑛𝑖𝑡𝑖𝑎𝑙 𝑐𝑎𝑠𝑒𝑠 (𝑏𝑒𝑓𝑜𝑟𝑒 𝑒𝑥𝑐𝑙𝑢𝑠𝑖𝑜𝑛 𝑐𝑟𝑖𝑡𝑒𝑟𝑖𝑎)
𝑋 100 
Formula 1. Cleaning index calculus. Formula of Cleaning index calculus according to additional 
exclusion criteria 
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Finally, a case/non-case strategy of analysis was performed by calculating the reporting 
odds ratio (ROR) with respective 95% of confidence interval (95%CI) for each drug (see Table 
3.2.2.1a and formula 2 and 3 below) (193).  
Table 3.2.2.1a. The 2x2 contingency table for ROR analysis. Table illustrate a general 
example of ROR calculus. 
  Drug of interest Total 
  Yes NO  
Adverse event of interest 
Yes A B A+B 
NO C D C+D 
Total  A+C B+D A+B+C+D 
A=reports containing suspect drugs + suspect adverse event (AD) 
B=Reports containing suspect AD + other reported drugs (excluding drug of interest) 
C=Reports with drug of interest + other ADs (excluding AD of interest) 
D=reports containing other drugs + other ADs  
 
 𝑅𝑒𝑝𝑜𝑟𝑡𝑖𝑛𝑔 𝑂𝑑𝑑𝑠 𝑅𝑎𝑡𝑖𝑜 =
A/C
B/D
 
Formula 2. Reporting odds ratio calculus. Reporting odds ratio calculus according to table 
3.2.2.1a. 
 95%𝐶𝐼 = 𝑒ln(𝑅𝑂𝑅) ± 1.96 𝑥 √
1
𝐴
+
1
𝐵
+
1
𝐶
+
1
𝐷
 
Formula 3. ROR confidence intervals calculus. The 95% confidence interval (upper and lower 
limits) calculus according to table 3.2.2.1a. 
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Disproportionally signal was detected when drug had significant ROR (lower limit above 1), 
at least 10 cases and cleaning index equal or higher than 70% (see article 2 in the end of the thesis 
for more details). 
Additionally, since the incidence of MS is higher in female sex, we performed a sensitivity 
analysis of drugs by considering sex strata subjects.  
3.2.2.2 Part 3: MS therapies and DILI events 
 
For this study, we included 13 years of FAERS data from q1-2004 to q4-2016 by applying 
the datamining techniques (see the previous section). This study aimed to detect possible 
idiosyncratic liver injury (DILI) signals in MS treated individuals. In this case, we included reports 
with at least one PT associated with DILI events according to two strategies of analysis: only Severe 
liver injury (SLI) by using a dedicated MedDRA query and Overall liver injury (OLI) by using a 
selection of specific PTs  (194, 195). Exposure were defined as presence of disease treatment 
authorized for MS such as modifying therapies (Interferon beta-1a, interferon beta-1b, glatiramer 
acetate, fingolimod, teriflunomide, dimethyl fumarate, mitoxantrone, natalizumab, alemtuzumab, 
daclizumab) and symptomatic drug (fampridine). Since alemtuzumab and daclizumab have also 
other therapeutic indications we selected only cases presenting substance name + MS indication in 
INDIPT field or substance + MS authorized brand name (Lemtrada and Zinbryta).  
A case/non-case analysis was performed: for each included drug the Reporting Odds Ratio 
(ROR) with 95% confidence interval (95CI) was calculated. Signal was claimed when at least 3 cases 
where retrieved and 95CI lower limit exceeded 1. In addition, since analysis focused on drugs 
rather than patients, and therefore possible alternative cause of DILI events may account in the 
observed events, we adjusted the RORs for co-reported drugs previously associated with DILI 
events (194, 196-198).  
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Finally, presence of concomitant therapies associated with DILI events were also assessed 
in a case-by-case analysis. Presence of hepatotoxic drugs as well as drugs for hepatitis were 
evaluated and ranked according to the recent categorization proposed by Bjornsson (199), which 
includes five categories based on number of published case reports: A (with ≥ 50 published 
reports), B (12-49), C (4-11), D (1-3), E (none) (199).  
The analyses of part 2 and 3 were performed by using PostgreSQL program (200) and R 
software (201).  
 3.2 Ethical issues  
 
In this thesis, we used aggregate and anonymous data therefore the ethical authorization is 
not requested.  
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4. RESULTS 
 
 4.1 Part 1: Evidence mapping of the literature  
Results showed in this section were published in relevant article (202). 
In order to evaluate possible role of drugs in MS development we first conducted a review 
of available evidence by an evidence mapping approach.  
From 832 potential eligible studies retrieved by using specific search strategy in Medline 
and Embase, 44 articles were included and 14 ones were added after snowballing of 5 reviews 
(Figure 4.1a).  
 
 
 
Figure 4.1a. Flowchart of literature selection and final included articles.  
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Analysis of included articles showed possible presence of two outcomes in the same 
paper, therefore  46 out of 58 articles provided data on MS onset and 14 on its worsening  (Table 
4.1a and 4.1b). 
As indicated in table 4.1a and 4.1b drugs acting on immune system were the most studied 
drugs and the relevant evidence included several case reports and case series as well as 
longitudinal studies. The major number of case reports and case series occurred in patients 
treated with infliximab, adalimumab and etanercept. After the application of Naranjo algorithm, a 
score between possible and probable were ascribed to these reports.   
As for drugs acting on nervous system, valproic acid was associated with increased risk to 
develop MS in the unique available cohort study (Hazard Ratio: 2.41; 95%Cl: 1.32-4.43), whereas 
contrasting results were obtained for anesthetics (see supplemental material of study 2 for 
details).   
Oral contraceptives were the most investigated drugs, albeit with contrasting results.  
Three cohort studies and one case-control study showed a protective effect of these therapies in 
MS onset and worsening, whereas one case-control study found a possible relationship between 
contraceptive use and increased MS risk; and three cohort studies did not find any association 
(table 4.1a and 4.1b). As regards assisted reproduction treatments increased number of relapses 
were observed in 2 cohort studies and 1 case series.  
Antibiotics were investigated in two studies: Alonso et al. (203) reported no association 
between antibiotics and MS onset, whereas Norgaard et al. (204) found an increased number of 
events in exposed individuals.  
Other valuable evidence includes a case report, that suggests possible association between 
use of cannabinoid receptor-1 antagonist and new MS onset, and a cohort study that found no 
55 
 
association between amiloride exposure and MS onset and worsening (Hazard Ratio: 1.34; 
95%CI:0.81-2.20).  
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Table 4.1a Synopsis of literature results: drugs and onset of Multiple Sclerosis. 
ONSET 
Drug Type of study 
 Randomized 
controlled trials  
Cohort 
study 
Case 
control 
Case 
series 
Case 
report 
Drugs acting on immune system (24) 
Adalimumab     ↑ (7) 
Etanercept     ↑ (8) 
Infliximab  ↔ (1)   ↑ (6) 
TNF antagonist  ↔ (1) ↓ (1) ↑ (1)  
Anakinra   ↑ (1)   
Methotrexate   ↔ (1)   
Leflunomide   ↔ (1)   
Hydroxychloroquine/chloroquine    ↔ (1)   
Other DMARDs   ↑  (1)   
Interferon alfa    ↑ (1) ↑ (1) 
Drugs acting on nervous system (4) 
Valproic acid  ↑ (1)    
Anaesthetic  ↑ (2) ↔ (2)   
Drugs acting on endocrine system (9) 
Contraceptive  ↔ (3) 
↓ (2) 
↑ (1) 
↓ (1) 
  
Diethylstilbestrol  ↔ (1)    
Synthetic human type insulin    ↑ (1)  
Drugs acting on microbial infections (5) 
Penicillin   ↓ (1) 
↑ (1) 
  
Cephalosporin   ↔ (1)   
Tetracyclines   ↔ (1) 
↑ (1) 
  
macrolides   ↔ (1) 
↑ (1) 
  
Pivmecillinam   ↑ (1)   
Sulfonamide/Trimethroprim   ↑ (1)   
Nitrofurantoin   ↑ (1)   
Quinolones   ↔ (1)   
HIV treatment  ↓ (1)    
Ethambutol    ↑ (1)  
Sulfasalazine     ↑ (1) 
Other antibiotics   ↑ (1) 
↔ (1) 
  
Others (4) 
Amiloride ↔ (1)     
Histamine 1 receptor blockers   ↓ (1)   
Cannabinoid receptor-1b antagonist 
(rimonabant) 
    ↑ (1) 
Drug abuse   ↑ (1)   
NOTE: A single article counts as many fold as the number of drug-event pair investigated. A single article 
may be cited in both tables 1 and 2.  
↑ increased risk ↓ decreased risk ↔ no association. 
Antonazzo et al; Drug Saf. 2017 Sep;40(9):823-834 (205) 
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Table 4.1b Synopsis of literature results: drugs and worsening of Multiple Sclerosis.  
WORSENING 
Drug Type of study     
 Randomized 
controlled 
trials  
Cohort 
study 
Case 
control 
Case 
series 
Case 
report 
Drugs acting on immune system (5)      
Interferon gamma ↑ (1)     
Atacicept ↑ (1)     
TNF antagonist ↑ (1)   ↑ (1)  
Lenercept ↑ (1)     
Drugs acting on nervous system (3)      
Fluoxetine     ↑ (1) 
Carbamazepine    ↑ (1)  
Anaesthetic  ↔ (1)    
Drugs acting on endocrine system (5)      
Contraceptive  ↓ (2)    
Assisted reproduction treatment  ↑ (2)  ↑ (1)  
Others (1)      
Amiloride  ↔ (1)    
NOTE: A single article counts as many fold as the number of drug-event pair investigated. A single 
article may be cited in both tables 1 and 2. 
↑ increased risk ↓ decreased risk ↔ no association.  
Antonazzo et al; Drug Saf. 2017 Sep;40(9):823-834 (205). 
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Causality assessment, by using Naranjo algorithm, for the majority of case reports and case 
series  pointed out a possible or probable link between drug exposure and observed adverse event 
(see supplemental material of article 2 at the end of this thesis).  
The assessment of quality of case reports and case series by using ISPE and ISO guidelines 
revealed a general paucity of important data in the reports such as medical history of patient, 
presence of concomitant therapies, physical examination results and other parameters useful to 
assess the plausibility of suspected association between drug and reported adverse event (Figure 
4.1a).  
Missing or not gradable data were observed also in longitudinal studies by using 
Newcastle-Ottawa scale. In particular, in case–control studies, authors did not report non-
response rate and how exposure was ascertained (Figure 4.1b). As regards cohort studies, all 
included records showed some missing data among evaluated items (Figure 4.1b); the main 
limitations were detected in follow-up of the cohort that seems inadequate for the aim of the 
studies (evaluation of MS onset), the non-comparability of the cohorts and the absence of 
assessment of disease at the date entry (Figure 4.1b).  
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Figure 4.1a Quality assessment of case reports and case series. Antonazzo et al; Drug Saf. 2017 Sep;40(9):823-834 (205). 
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Figure 4.1.b. Quality assessment of case control and cohort studies. Antonazzo et al; Drug Saf. 2017 
Sep;40(9):823-834 (205). 
 
 
 
 
 
Case-control studies 
Cohort studies 
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4.2 Part 2: Drug-induced multiple sclerosis  
 
Results showed in this section were published in relevant article (205).  
After analyzing the relevant literature, we investigated new signals of possible drug 
contribution in multiple sclerosis occurrence by using the Food and Drug Administration Event 
Reporting System database (FAERS). Over the 13 years of data collection (from 01/01/2004 to 
30/06/2016), FAERS database collected 8,238,509 reports. Among them after data mining and 
application of exclusion criteria 5,202,124 reports were included in the analysis. From this 
database we selected 3,226 cases (indicating “multiple sclerosis” as ADR) and 5,198,898 non-cases 
(Figure 4.2 a). 
 
 
 
 
 
 
 
 
 
 
  
Raw Database 
(01/01/2004-
30/06/2016) 
8,238,509 Exclusion criteria: 
- Duplicates and 
uncodified
a
 records  
1,498,265 
  
Records containing 
“Multiple Sclerosis” as 
PT (cases) 
3,226 
Other records  
(non cases) 
5,198,898 
Additional exclusion criteria: 
- Step 1. Records with MS Drugs:  1,517,448 
- Step 2. Records with IndiPT “Multiple 
Sclerosis”: 1,979 
- Step 3. Records with Vaccines- ATC code 
J07*: 18,893 
Curated  
database 
5,202,124 
Clean database   
6,740,244 
Figure 4.2a. Synopsis of case and non-cases selection.   
a: based on ATC classification and MedDRA terminology. 
PT: preferred term of the MedDRA terminology 
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Most of the included cases were female, aged 30-65 years and lived in USA. For 2,666 
(83%), only a single drug was reported as suspected agent. The highest percentage of reports were 
submitted by consumers and physicians (74%).  
According to criteria to define a signal (at least 10 cases, cleaning index ≥70% and 
significant ROR), immunomodulating drugs were the most reported drugs (1,343 cases), of them 
etanercept (445 cases, ROR 2.48; 95%Ci: 2.24-2.74), adalimumab (329, 2.05; 183-2.30), and 
infliximab (119, 2.25; 187-2.70) were the most frequently reported with also higher cleaning index 
(Table 2.1a).  
 Significant RORs, albeit with less cases, were found also for drugs acting on nervous 
system and musculo-skeletal system: varenicline (80, 2.05; 1.64-2.56), clozapine (33, 1.43;1.01-
2.01), desvenlafaxine (13, 1.95; 1.13-3.37), alendronic acid (50, 2.56; 1.93-3.389) and its salt (14, 
2.63; 1.56-4.45).  
Sildenafil (27, 1.87; 1.28-2.73) typically used by men and etonorgestrel (46, 2.20; 1.64-
2.94) used as contraceptive drugs by women showed significant disproportionality.  
As showed in table 4.2a application of cleaning index (see method for details) allowed to 
exclude from the analysis drugs with possible misleading results because erroneously associated 
with multiple sclerosis events. Drugs such as baclofen, gabapentin and its analogue pregabalin, 
and methylprednisolone were excluded from significant results, and in fact they are also widely 
used as symptomatic drugs during first episode and subsequent relapses of MS.   
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Table 4.2a Reporting Odds Ratio (ROR) of active substances (ATC V level). In bold, drugs with 
statistically significant ROR (see methods for details).  Expert Opin Drug Saf. 2018 Jul 30 (202). 
Substance ATC code N (%)a Sex 
M/F/UNK 
ROR (95%Cl) 
ANTINEOPLASTIC AND IMMUNOMODULANTING AGENTS (ATC: L) 
Etanercept L04AB01 445 (93) 111/291/43 2.48 (2.24 - 2.74) 
Adalimumab L04AB04 329 (81) 94/214/21 2.05 (1.83 - 2.30) 
Infliximab L04AB02 119 (88) 33/79/7 2.25 (1.87 - 2.70) 
Methotrexate L01BA01 39 (78) 4/32/3 1.87 (1.36 - 2.56) 
Ustekinumab L04AC05 36 (100) 16/16/4 4.97 (3.57 - 6.90) 
Peginterferon alfa-2a L03AB11 31 (78) 15/14/2  1.13 (0.79 - 1.61) 
Abatacept L04AA24 31 (86) 7/21/3 3.78 (2.65 - 5.39) 
Golimumab L04AB06 28 (93) 1/26/1 3.70 (2.55 - 5.37) 
Imatinib L01XE01 15 (88) 5/10/0 0.96 (0.58 - 1.60) 
Tocilizumab L04AC07 15 (88) 2/11/2 1.90 (1.14 - 3.15) 
Rituximab L01XC02 14 (39) 2/11/1 0.60 (0.36 - 1.02) 
Certolizumab pegol L04AB05 13 (100) 3/9/1 1.20 (0.70 - 2.08) 
Ciclosporin L04AD01 13 (76) 6/7/0 0.89 (0.51 - 1.53) 
Trastuzumab L01XC03 12 (75) 0/12/0 1.34 (0.76 - 2.36) 
Mycophenolic acid L04AA06 11 (79) 2/9/0 1.87 (1.03 - 3.38) 
Interferon alfa-2b L03AB05 10 (100) 2/8/0 5.10 (2.74 - 9.50) 
NERVOUS SYSTEM (ATC: N) 
Pregabalin N03AX16 112 (59) 24/82/6 2.98 (2.47 - 3.60) 
Varenicline N07BA03 80 (81) 14/59/7 2.05 (1.64 - 2.56) 
Gabapentin N03AX12 70 (41) 23/44/3 3.72 (2.93 - 4.71) 
Quetiapine N05AH04 69 (63) 13/55/1 2.15 (1.69 - 2.73) 
Duloxetine N06AX21 39 (47) 4/35/0 1.58 (1.15 - 2.16) 
Paracetamol N02BE01 37 (32) 8/28/1 1.03 (0.75 - 1.43) 
Fentanyl N02AB03 34 (59) 5/29/0 1.29 (0.92 - 1.80) 
Sodium oxybate N07XX04 34 (64) 1/33/0 3.86 (2.75 - 5.42) 
Venlafaxine N06AX16 31 (55) 4/26/1 1.94 (1.36 - 2.76) 
Clozapine N05AH02 33 (70) 13/20/0 1.43 (1.01 - 2.01) 
Sertraline N06AB06 28 (52) 7/18/3 1.66 (1.14 - 2.41) 
Olanzapine N05AH03 23 (64) 3/20/0 1.27 (0.84 - 1.92) 
Acetylsalicylic acid N02BA01 22 (59) 6/16/0 0.85 (0.56 - 1.29) 
Risperidone N05AX08 21 (54) 2/19/0 1.09 (0.71 - 1.68) 
Paroxetine N06AB05 21 (70) 4/16/1 1.02 (0.67 - 1.57) 
Carbamazepine N03AF01 20 (34) 5/14/1 2.02 (1.30 - 3.14) 
Oxycodone N02AA05 17 (40) 4/12/1 0.83 (0.51 - 1.34) 
Lamotrigine N03AX09 17 (71) 0/16/1 0.89 (0.55 - 1.43) 
Levetiracetam N03AX14 16 (55) 3/12/1 1.39 (0.85 - 2.27) 
Topiramate N03AX11 15 (43) 1/13/1 1.61 (0.97 - 2.67) 
Buprenorphine N02AE01 13 (76) 3/10/0 0.95 (0.55 - 1.64) 
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Desvenlafaxine N06AX23 13 (72) 2/11/0 1.95 (1.13 - 3.37) 
Morphine N02AA01 12 (35) 4/8/0 0.99 (0.56 - 1.74) 
Fluoxetine N06AB03 12 (55) 3/9/0 1.09 (0.62 - 1.91) 
Bupropion N06AX12 11 (33) 0/11/0 0.73 (0.41 - 1.33) 
Modafinil N06BA07 11 (21) 1/10/0 3.12 (1.72 - 5.64) 
Caffeine N06BC01 11 (73) 4/7/0 4.05 (2.24 - 7.33) 
Eletriptan N02CC06 10 (91) 4/6/0 7.6 (4.08 - 14.16) 
Lithium carbonate N05AN01 10 (50) 7/3/0 2.44 (1.31 - 4.54) 
Lorazepam N05BA06 10 (59) 3/6/1 1.73 (0.93 - 3.22) 
ALIMENTARY TRACT AND METABOLISM (ATC: A) 
Esomeprazole A02BC05 80 (78) 9/70/1 3.17 (2.54 - 3.96) 
Insulin lispro A10AB04 33 (89) 9/24/0 1.54 (1.09 - 2.17) 
Insulin (human) A10AB01 20 (87) 8/12/0 1.90 (1.23 - 2.95) 
Insulin glargine A10AE04 16 (73) 4/12/0 0.89 (0.54 - 1.45) 
Omeprazole A02BC01 11 (37) 0/11/0 0.86 (0.48 - 1.56) 
MUSCULO-SKELETAL SYSTEM (ATC: M) 
Baclofen M03BX01 98 (49) 27/66/5 9.83 (8.04 - 12.03) 
Rofecoxib M01AH02 54 (56) 17/37/0 1.79 (1.37 - 2.35) 
Zoledronic acid M05BA08 53 (54) 8/43/2 1.72 (1.31 - 2.26) 
Alendronic acid M05BA04 50 (83) 1/43/6 2.56 (1.93 - 3.38) 
Celecoxib M01AH01 27 (57) 5/21/1 1.34 (0.91 - 1.95) 
Denosumab M05BX04 26 (87) 0/23/3 1.32 (0.90 - 1.95) 
Botulinum toxin M03AX01 21 (68) 1/20/0 2.28 (1.48 - 3.50) 
Pamidronic acid M05BA03 12 (27) 0/12/0 2.57 (1.46 - 4.53) 
Ibandronic acid M05BA06 12 (86) 0/10/2 1.43 (0.81 - 2.52) 
Alendronate sodium M05BA05 14 (78) 0/14/0 2.63 (1.56 - 4.45) 
GENITO-URINARY SYSTEM AND SEX HORMONES (ATC: G) 
Ethinylestradiol G03CA01 65 (73) 0/60/5 1.26 (0.99 - 1.61) 
Etonorgestrel G03AC08 46 (84) 0/41/5 2.20 (1.64 - 2.94) 
Levonorgestrel G03AC03 38 (78) 0/38/0 0.73 (0.53 - 1.01) 
Sildenafil G04BE03 27 (96) 26/0/1 1.87 (1.28 - 2.73) 
Medroxyprogesterone G03AC06 11 (42) 0/11/0 0.48 (0.26 - 0.86) 
Tolterodine G04BD07 11 (61) 1/10/0 3.61 (1.99 - 6.52) 
Drospirenone and estrogen G03AA12 10 (67) 0/10/0 0.50 (0.27 - 0.92) 
Conjugated estrogens G03CA57 10 (38) 0/10/0 0.42 (0.23 - 0.79) 
OTHER DRUGS 
Teriparatide H05AA02 68 (67) 3/65/0 1.28 (1.01 - 1.63) 
Ribavirin J05AB04 39 (70) 14/24/1 1.03 (0.75 - 1.42) 
Atorvastatin C10AA05 35 (69) 12/19/4 1.09 (0.78 - 1.52) 
Isotretinoin D10AD04 30 (81) 16/13/1 1.68 (1.17 - 2.41) 
Rosuvastatin C10AA07 29 (76) 6/22/1 1.46 (1.01 - 2.10) 
Omalizumab R03DX05 21 (88) 1/19/1 2.11 (1.37 - 3.24) 
Levofloxacin J01MA12 19 (73) 1/14/4 1.62 (1.03 - 2.55) 
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Valsartan C09CA03 17 (71) 4/13/0 1.01 (0.63 - 1.63) 
Octreotide H01CB02 16 (100) 1/15/0 2.01 (1.23 - 3.29) 
Somatropin H01AC01 15 (83) 1/13/1 1.49 (0.90 - 2.48) 
Budesonide R01AD05 15 (79) 0/15/0 1.07 (0.65 - 1.78) 
Methylprednisolone H02AB04 14 (5) 3/11/0 1.90 (1.12 - 3.21) 
Salmeterol R03AC12 13 (72) 2/11/0 0.64 (0.37 - 1.10) 
Fluticasone R03BA05 13 (50) 2/11/0 0.53 (0.3 - 0.91) 
Prednisone H02AB07 12 (15) 2/10/0 0.68 (0.39 - 1.20) 
Formoterol R03AC13 12 (86) 1/11/0 1.00 (0.57 - 1.77) 
Naloxone  V03AB15 12 (86) 2/10/0 1.82 (1.03 - 3.21) 
(a) Cleaning index 
 
The sex stratified analysis showed distribution of female component among retrieved 
cases (table 4.2b). Data were in line with the general analysis apart for few drugs which lost 
significance in male group due to low number of cases (table 4.2b).   
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Table 4.2b. Reporting Odds Ratio (ROR) of active substances (ATC V level) in sex stratification. In bold, 
drugs with statistically significant ROR (see methods for details) 
Substance Female 
N   
ROR (95%Cl) Male 
 N  
ROR (95%Cl) 
ANTINEOPLASTIC AND IMMUNOMODULANTING AGENTS 
Etanercept 291 1.85 (1.64 - 2.1) 111 4.16 (3.40 - 5.10) 
Adalimumab 214 1.56 (1.36 - 1.8) 94 3.15 (2.54 - 3.92) 
Infliximab 79 2.06 (1.65 - 2.58) 33 2.80 (1.97 - 3.97) 
Ustekinumab 16 3.87 (2.36 - 6.33) 16 7.57 (4.61 - 12.44) 
Abatacept 21 2.60 (1.69 – 4.00) 7 8.56 (4.06 - 18.04) 
Golimumab 26 3.92 (2.66 - 5.77) 1 0.80 (0.11 - 5.70) 
Tocilizumab 11 1.51 (0.84 - 2.73) 2 1.76 (0.44 - 7.05) 
Mycophenolic acid 9 2.86 (1.48 - 5.50) 2 1.08 (0.27 - 4.34) 
Methotrexate 32 2.04 (1.44 - 2.89) 4 1.01 (0.38 - 2.71) 
Interferon alfa-2b 8 8.05 (4.01 - 16.15) 2 3.36 (0.84 - 13.48) 
NERVOUS SYSTEM  
Varenicline 59 1.98 (1.53 - 2.56) 14 1.72 (1.01 - 2.92) 
Clozapine 20 1.80 (1.16 - 2.80) 13 1.59 (0.92 - 2.75) 
Desvenlafaxine 11 1.81 (1.00 - 3.27) 2 2.27 (0.57 - 9.08) 
Caffeine 7 3.11 (1.48 - 6.55) 4 8.39 (3.14 - 22.46) 
Eletriptan 6 4.63 (2.07 - 10.33) 4 36.42 (13.54 - 97.95) 
ALIMENTARY TRACT AND METABOLISM  
Esomeprazole 70 3.20 (2.52 - 4.06) 9 2.00 (1.04 - 3.87) 
Insulin lispro 24 1.54 (1.03 - 2.30) 9 1.76 (0.91 - 3.39) 
Insulin (human) 12 1.61 (0.91 - 2.83) 8 3.08 (1.53 - 6.18) 
MUSCULO-SKELETAL SYSTEM 
Alendronic acid 43  2.01 (1.49 - 2.72) 1 1.18 (0.17 - 8.42) 
Alendronate sodium 14 2.39 (1.41 - 4.05) -- --- 
GENITO-URINARY SYSTEM AND SEX HORMONES  
Etonogestrel 41 1.68 (1.23 - 2.29) -- --- 
Sildenafil -- --- 26 4.18 (2.82 - 6.19) 
OTHER DRUGS 
Isotretinoin 13 1.13 (0.65 - 1.94) 16 3.54 (2.16 - 5.81) 
Rosuvastatin 22 1.56 (1.02 - 2.37) 6 1.24 (0.55 - 2.77) 
Omalizumab 19 2.25 (1.43 - 3.54) 1 0.58 (0.08 - 4.11) 
Levofloxacin 14 1.65 (0.97 - 2.79) 1 0.38 (0.05 - 2.73) 
Octreotide 15 2.78 (1.67 - 4.63) 1 0.50 (0.07 - 3.52) 
Naloxone 10 2.65 (1.42 - 4.94) 2 1.29 (0.32 - 5.16) 
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4.3 Part 3: MS therapies and idiosyncratic liver injury (DILI) events 
 
Results showed in this in this section were published in relevant article (206). 
In the third part of the thesis, from the curated FAERS database, we selected 11,764 cases 
of DILI and we grouped them as follows: 8,982 overall liver injury (OLI) and 4,873 severe liver 
injury (SLI) (Figure 4.3a). Cases were mainly female (75%), aged 30 years or older, and most of 
them reported only one MS therapy as suspected drug (99%).  
 
 
Figure 4.3a. Synopsis of cases selection 
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Interferons and mitoxantrone had been already associated with DILI. In fact, they were 
already classified in class A (interferons) and D (mitoxantrone) according to Bjornsson et al., based 
on the number of published reports of liver injury (199). In our analyses they showed significant 
RORs with high ROR in almost  all performed analyses (Table 4.3a and table 4.3b).   
As for OLI analysis, a more generic DILI classification, several drugs had significant results 
(Table 4.3a). In this case, some drugs showed disproportionality signals among the rest of MS 
therapies (right part of table). Additionally, results performed among the entire database FAERS 
had similar results (left part of table). Among these therapies fingolimod and teriflunomide 
showed significant results (RORadj: 2.53; 95%CI: 2.40-2.66) and (2.31; 2.12-2.52) respectively, 
followed by mitoxantrone (2.10; 1.81-2.42) and alemtuzumab (1.34; 1.09-1.65).  
The only therapy different from the disease modifying ones, approved specifically for MS 
symptoms, reported signal of disproportionality with significant ROR (1.58; 1.15-2.17; Table 4.3a) 
in OLI analysis and (2.27; 1.59-3.26; Table 4.3b) in SLI analysis. 
Analysis focused on only severe events had slightly different pattern of disproportionality 
(Table 4.3.b). Fingolimod showed a signal of disproportionality in non-adjusted ROR (RORraw: 
1.13; 95%CI:1.03-1.24) that disappeared in adjusted analysis (RORadj: 1.09; 0.99-1.20). Also 
mitoxantrone had similar pattern, but in this case it still maintained statistically significant values 
(RORraw: 3.04; 2.54-3.62) and (RORadj: 2.51; 2.10-3.00).  
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Table 4.3a. Disproportionality analyses according with Overall Liver Injury classification. In bold: statistically significant disproportionality 
(i.e., the lower limit of the 95%CI of ROR>1).  
    Overall Liver Injury (OLI)     
Drug    General database(A)   Multiple sclerosis database(B) 
 Total 
reports 
 N cases ROR (95%CI)   ROR (95%CI) RORadj (95%CI) 
Moderate efficacy or standard initial disease modifying therapies 
Interferon beta-1a 146,470  3,368 0,9 (0,87-0,93)  1.10 (1.05-1.15) 1.15 (1.10-1.2) 
Glatiramer acetate 18,591  274 0,57 (0,51-0,65)  0.70 (0.62-0.79) 0.69 (0.61-0.78) 
Interferon beta-1b 22,053  878 1,59 (1,48-1,7)  1.94 (1.8-2.08) 1.86 (1.73-1.99) 
Fingolimod  38,563  1,823 1,9 (1,81-1,99)  2.32 (2.20-2.44) 2.53 (2.40-2.66) 
Teriflunomide 11,945  578 1,95 (1,79-2,12)  2.37 (2.18-2.59) 2.31 (2.12-2.52) 
Dimethyl fumarate 50,182  397 0,31 (0,28-0,34)  0.37 (0.34-0.41) 0.34 (0.31-0.37) 
High efficacy or later disease modifying therapies 
Mitoxantrone 3,880  199 2,07 (1,79-2,39)  2.52 (2.19-2.92) 2.10 (1.81-2.42) 
Natalizumab 136,180  1,452 0,41 (0,39-0,43)  0.50 (0.48-0.53) 0.44 (0.42-0.47) 
Alemtuzumab 2,822  93 1,30 (1,06-1,6)  1.59 (1.29-1.96) 1.34 (1.09-1.65) 
Daclizumab
(C) 
166  3 0,7 (0,22-2,21)  0.86 (0.27-2.69) 0.81 (0.26-2.53) 
Symptomatic therapy 
Fampridine 1,145  40 2,07 (1,79-2,39)  1.69 (1.23-2.32) 1.58 (1.15-2.17) 
ROR: Reporting odds Ratio; RORadj: ROR adjusted for concomitant hepatotoxic drugs;  NA: not applicable (number of cases<3).  
(A) Analysis performed considering the entire FAERS database. 
(B) Analysis performed only within Multiple sclerosis drugs. 
(C) Withdrawn by the European Medicines Agency for serious drug-induced events (liver injury and encephalitis). 
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Table 4.3b  Disproportionality analyses based on the Standardized MedDRA Query “Drug-related hepatic disorders – severe events only”.  
In bold: statistically significant disproportionality (i.e., the lower limit of the 95%CI of ROR>1). 
    Severe Liver injury (SLI)     
Drug    General database
(A)
   Multiple sclerosis 
database
(B)
 
 
 Total 
reports 
 N cases ROR (95%CI)   ROR (95%CI) RORadj (95%CI) 
Moderate efficacy or standard initial disease modifying therapies 
Interferon beta-1a 146,470  2,343 0,76 (0,73-0,79)  1.41 (1.33-1.49) 1.78 (1.68-1.88) 
Glatiramer acetate 18,591  212 0,54 (0,47-0,62)  1.00 (0.87-1.15) 1.01 (0.88-1.16) 
Interferon beta-1b 22,053  535 1,16 (1,06-1,26)  2.16 (1.97-2.37) 2.09 (1.91-2.29) 
Fingolimod  38,563  496 0,61 (0,56-0,66)  1.13 (1.03-1.24) 1.09 (0.99-1.20) 
Teriflunomide 11,945  158 0,63 (0,53-0,73)  1.16 (0.99-1.37) 1.09 (0.93-1.28) 
Dimethyl fumarate 50,182  223 0,21 (0,18-0,24)  0.39 (0.34-0.44) 0.35 (0.31-0.40) 
High efficacy or later disease modifying therapies 
Mitoxantrone 3,880  131 1,63 (1,37-1,94)  3.04 (2.54-3.62) 2.51 (2.10-3.00) 
Natalizumab 136,180  759 0,26 (0,24-0,28)  0.49 (0.45-0.53) 0.43 (0.39-0.46) 
Alemtuzumab 2,822  33 0,55 (0,39-0,78)  1.03 (0.73-1.45) 0.85 (0.60-1.21) 
Daclizumab
(C) 
166  1 NA  NA  NA  
Symptomatic therapy 
Fampridine 1,145  31 1,30 (0,91-1,86)  2.42 (1.69-3.46) 2.27 (1.59-3.26) 
ROR: Reporting odds Ratio; RORadj: ROR adjusted for concomitant hepatotoxic drugs;  NA: not applicable (number of cases<3).  
(A) Analysis performed considering the entire FAERS database. 
(B) Analysis performed only within Multiple sclerosis drugs. 
(C) Withdrawn by the European Medicines Agency for serious drug-induced events (liver injury and encephalitis). 
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According to Bjornsson (199), 4 out of 11 studied drugs had categorized as hepatotoxic drugs: 
interferons (class A), natalizumab (C) and mitoxantrone (D). 
When concomitant therapies were analyzed in the case-by-case analysis, only in a few cases 
drugs specifically used to treat hepatitis infections were found; in particular OLI cases indicated only 
drugs used to treat HBV whereas SLI cases both HBV and HCV drugs (Table 4.3c).  As regards the rest of 
drugs, about 40% of cases reported concomitant use of drugs potentially involved in DILI events. 
However, only a minority of cases had drugs classified as class A (with huge number of published cases). 
Analysis of concomitant drugs pointed also out that the most reported drugs were therapies generally 
used during first symptoms and relapse of disease such as baclofen (546 cases), gabapentin (523) 
ibuprofen (500), and other more generic and largely used in the general population such as clonazepam 
(243) and omeprazole (216).  
  
72 
 
Table 4.3c.  Case by case analysis of DILI reports.  
Drug   Overall Liver Injury (OLI)   Severe Liver Injury (SLI)
(A)
 
    N. of cases with concomitant hepatotoxic 
agents
(B)
, with relevant DILI categorization 
Reported use of 
anti-hepatitis drug 
 
(C)
 
  N. of cases with concomitant 
hepatotoxic agents
(B)
, with relevant 
DILI categorization 
Reported use of 
anti-hepatitis drug 
 
(C)
 
 DILI 
risk 
(B)
 
 N cases N (%) A B C D   N cases N (%) A B C D  
Moderate efficacy or standard initial disease modifying therapies 
Interferon beta-1a A  3,368 1,332 
(40) 
541 
(16) 
641 
(19) 
751 
(22) 
582 
(17) 
N  2,343 849 
(36) 
329 
(14) 
454 
(19) 
475 
(20) 
411 
(18) 
Y (2) 
Glatiramer acetate   274 97 
(35) 
40 
(15) 
39 
 (14) 
48  
(18) 
41 
(15) 
N  212 67 
(32) 
18 
 (8) 
35 
(17) 
37 
(17) 
32 
 (15) 
N 
Interferon beta-1b A  878 394 
(45) 
191 
(22) 
182 
(21) 
205 
(23) 
209 
(24) 
N  535 225 
(42) 
98 
(18) 
110 
(21) 
124 
(23) 
101 
(19) 
N 
Fingolimod    1,823 746 
(40) 
213 
(12) 
372 
(20) 
476 
(26) 
338 
(19) 
N  496 210 
(42) 
64 
(13) 
108 
(22) 
123 
(26) 
101 
(20) 
Y (1) 
Teriflunomide   578 230 
(40) 
64 
(11) 
127 
(22) 
135 
23) 
121 
(21) 
N  158 51 
(32) 
12  
(8) 
22 
(14) 
38 
(24) 
28 
 (18) 
N 
Dimethyl fumarate   397 103 
(26) 
28 
(7) 
58 
 (15) 
68  
(17) 
65 
(16) 
N  223 58 
(26) 
15 
 (7) 
33 
(15) 
42 
(19) 
38 
 (17) 
N 
High efficacy or later disease modifying therapies 
Mitoxantrone D  199 180 
(90) 
43 
(22) 
98 (49) 161 
(81) 
70 
(35) 
Y (2)  131 117 
(89) 
22 
(17) 
60 
(46) 
103 
(79) 
48 (37) Y (4) 
Natalizumab C  1,452 284 
(16) 
86 
(6) 
144 
(10) 
179 
(12) 
151 
(10) 
Y (1)  759 208 
(27) 
68 
(9) 
108 
(14) 
122 
(16) 
110 
(14) 
Y (1) 
Alemtuzumab   93 55 
(59) 
13 
(14) 
32 
 (34) 
38  
(41) 
23 
(25) 
N  33 20 
(61) 
--- 14 
(42) 
17 
(51) 
5 
(15) 
N 
Daclizumab
(D) 
  3 1 
(33) 
--- --- 1 
(33) 
--- N  1 1 
(100) 
--- --- 1 
(100) 
--- N 
Symptomatic therapy 
Fampridine   40 18 
(45) 
3 
(8) 
7 
(18) 
9 
(23) 
11 
(28) 
N  31 20 
(65) 
8  
(26) 
9 
 (29) 
9  
(29) 
10 
 (32) 
N 
(A) Based on the Standardized MedDRA Query “Drug-related hepatic disorders – severe events only”. 
(B) Categorization based on Bjornsson et al. (199)
 
(C) Including boceprevir, telaprevir, ribavirin, lamivudine, interferon alfa,  simeprevir, daclatasvir, sofosbuvir and multiple combinations; in parenthesis number of cases; Y=yes; N=no. 
(D) Withdrawn by the European Medicines Agency for serious drug-induced events (liver injury and encephalitis). 
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5. DISCUSSIONS 
 
Here below, we discuss the overall research activity by highlighting both strengths and 
limitations of the methods, as well as possible clinical implications of the main findings (202, 205, 
206).   
 
 5.1 Drugs as possible risk factors for MS occurrence 
 
In the part 1 and 2 (and relevant articles) we detected the role of drugs in MS onset. In 
particular, first we conducted a review of literature in order to evaluate the available evidence and 
its quality (part 1) (205). Then, we explored signals of MS after drug exposure by using the largest 
pharmacovigilance database FAERS (part 2) (202).  
From the analysis of the literature,  specific classes of drugs more than others seemed to 
have a detrimental effect on MS onset and its worsening. For example, immunomodulating agents 
were the most retrieved drugs in case reports, case series and longitudinal studies. They provided 
also significant results in FAERS database: they were the most reported drugs and 
disproportionality signals were found for many of them, especially for infliximab, adalimumab and 
etanercept. It should be recognized that possible exacerbation of demyelinating disease and more 
generic neurological adverse events are reported in the Summary of Product Characteristics (SPC) 
of some TNF-antagonist drugs (e.g., the European SPC of adalimumab (207)). However, this 
information sometime is very generic, frequently derived from indirect evidence, and therefore 
scarcely useful for both clinicians and researchers. Pharmacovigilance studies maintain an 
important role in defining possible impact of all TNF-antagonists agents on occurrence of MS. For 
this class of drugs, a dual mechanism of actions can be suggested; albeit their role in MS disease is 
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still debated, they 1) may represent per se cause of disease by dysregulating immune system or 2) 
may be proxy of previous or concomitant diseases (i.e., chohn’s disease or other autoimmune 
disease), which can trigger the development of a second autoimmune disease (208, 209).   
Drugs acting on hormonal homeostasis were emerged in evidence mapping (contraceptive 
and assisted reproduction treatment). Moreover, FAERS analysis pointed out also other drugs of 
the same area such as insulin (in the article it is classified into alimentary tract metabolism group, 
according to ATC code), etonorgestrel and sildenafil. As regards insulin, it should be acknowledged 
that some evidence suggest an interplay between MS and diabetes (210, 211). A possible 
hypothesis is that the two diseases may share common risk factors such as low vitamin D level as 
well pathological pathways; this raises concerns on possible increased risk to develop a second 
one of these autoimmune disease in patients already affected by the other one (212). Concerning 
contraceptives, etonorgestrel has been tested in an ongoing clinical trials as possible MS 
treatment (213). However, as highlighted in evidence mapping, contraceptives (usually, estrogens 
and progestinin in combinations) could have misleading results in both evidence mapping and 
FAERS due to increased number of relapses during pill-free period (214). Therefore, MS events 
could be erroneously associated with contraceptive rather their discontinuation. Another typical 
female drug class is represented by bisphosphonates, which showed statistically significant results 
in FAERS analysis. This class of drugs is generally used to treat osteoporosis, a disease that affects 
adult women. The two diseases (MS and osteoporosis), share several risk factors such as smoking, 
geographical distribution and estrogens levels  (215). Therefore, a mutual influence cannot be 
completely excluded in their pathogenesis, although their apparent relationship could also be due 
to common risk factors.  
Overall evidence on antimicrobials shows high uncertainty on the association with MS. The 
published studies have contrasting findings and FAERS analysis provided signal only for 
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levofloxacin. It should be recognized that antimicrobials treatments are usually brief cycles and 
therefore rarely associated by potential reporter with the occurrence of chronic 
neurodegenerative disorders (such as MS) for which latency between cellular damage and disease 
onset can be several years long. As a matter of fact, it should be remembered that, generally, 
reporters are more confident to signal adverse events that occur after few hours or days from 
treatment. This can generate a misleading results for some disorders when studied as possible 
ADR of drug exposure such as MS. For this reason, antimicrobial and similar agents are more prone 
to be studied with longitudinal studies, which should integrate inherent limitations of PhV studies.  
As general hypothesis, these agents can also be considered as proxy of infections, which could be 
the actual responsible for immune system dysregulation and consequent MS development, as 
some studies have already suggested for virus infections (216). These drugs are able to influence 
also intestinal microbiome during their therapeutic activity. A recent review, highlighted a possible 
link between intestinal microbiome perturbations and neurological/neurodegenerative diseases 
(i.e., MS) (217). The role of microbiome in humans is still far to be completely elucidated, but it is 
known that this “organ” produces mediators, which are able to influence immune system 
functions. Generally, antibiotic therapies generate depletion of some species with consequent 
growth of other ones; this disequilibrium in microbiota composition, can cause change in mediator 
productions, which are able to influence immunity system, which can trigger MS development  
(218). 
As regards the rest of drugs emerged from FAERS analysis, lack evidence are available to 
support biologic hypotheses on their role in MS onset. In fact, some of them can represent a 
spurious signal of disproportionality, due to large use of these drugs in the general population (e.g. 
esomeprazole) or possible use of medication in extreme early stage of disease (i.e., sildenafil).  
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It should be recognized that FAERS analysis showed new signals for several classes of 
drugs, which have never been previously investigated. In addition, FAERS provided signals also for 
drugs previously detected but with contrasting results. New studies on possible role of drugs in MS 
development should be planned in order to confirm or reject hypothesis generated with FAERS 
analysis. These studies, should also take into account weakness emerged from quality assessment 
of longitudinal studies identified by evidence mapping. In particular, they should include: more 
detailed inclusion criteria; longer follow-up; and analysis of other parameters with potential 
impact on disease. Finally, also case reports and case series, generally used to plan new PhV 
studies (and longitudinal ones), should indicate data on clinical history, concomitant therapies, 
clinical tests and other useful information that can be used in PhV analysis designs (although we 
are aware that not all variables are included in PhV databases) and studies on Health-care 
databases as well.  
Improvements in case report description together with adequate longitudinal study 
designs are essential to assess the real role of drugs in MS pathogenesis (cause Vs proxy of 
disease). These approaches can contribute in the achievement of a sort of personalized medicine, 
which allows to avoid some drugs (associated to disease) for patients potentially prone to develop 
MS. On the other hand, analysis of previous drug exposures (proxies) can help clinicians to detect 
potential diseases or pathogens, which could have a role in new MS cases. Finally, all data 
retrieved by using case reports, pharmacovigilance and longitudinal studies could provide a 
continuous updating of drugs’ SPC. These integrate approaches can contribute to highlight 
possible occurrence of demyelinating events during therapies which apparently have no relation 
with neurological ADRs. 
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 5.2 MS therapies and DILI events 
 
In the third part of the thesis, we explored FAERS database detecting signals of DILI events 
during MS treatments (206). New signals of disproportionality were found for some MS therapies, 
whereas for other drugs our results confirmed their hepatotoxic effects. 
 The first treatments approved specifically for MS were interferons and mitoxantrone. For 
these agents, our results confirmed their potential hepatotoxic effects. In fact, liver tests are 
recommended before new cycles of treatment and periodically during the therapy with 
recommendation to discontinue it if abnormalities of liver enzymes are observed (112-114, 121, 
155). Our findings for these drugs can be interpreted as “positive controls” in this study, adding 
weight to the reliability of adopted strategy of analysis.  
For the first time, we observed signal of DILI in patients treated with alemtuzumab, 
teriflunomide and fingolimod. Teriflunomide already received a warning for potential liver adverse 
effect based on leflunomide (its precursor) data (149, 150), and now we provide further for this 
concern. In light of different mechanisms of action of above drugs, several hypotheses of liver 
damage can be supposed. These include: 1) block of receptors on liver cell surface with 
consequent loss of function that can also stimulate auto-repair ability dysfunctions with 
consequent cellular death; 2) decreasing immune system reactivity, that can trigger new infection 
or reactivation of previous ones, with consequent liver damage; 3) finally, these modulating 
immune system drugs can create unbalance between immunity cells with over expression of 
specific mediators, such as cytokines, that influence liver cell life inducing apoptosis (219, 220).  
The only symptomatic drug specifically approved for treatment of MS symptoms is 
fampridine, which showed significant disproportion in FAERS analysis, thus increasing concerns on 
its safety profile. In clinical practice, fampridine can be co-prescribed with other MS disease 
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modifying therapies, however most cases no other MS therapies were reported (55% of cases). 
From basic research, new evidence of possible effect of fampridine on liver has been found: an 
animal study showed that rats exposed to fampridine can develop liver cell dysfunction (221). The 
mechanism is still far to be elucidated, however, the blockage of K+ channels or the Na+/K+ 
ATPase and modulation of pro- and anti-apoptotic gene expression can have a crucial role in the 
observed adverse effect.  
 Our study did not provide significant results for daclizumab, that was authorized for MS in 
summer 2016 and was withdrawn  by Biogen from the market in the subsequent winter due to 
fatal adverse events including liver damage (222). Several factors might influence our results. The 
short time on market and early restriction of its use by EMA can have impacted on its use in the 
general population and therefore on the occurrence of ADRs. In addition, we cannot completely 
excluded that the adopted strategy of analysis (drug + brand name and drug + therapeutic 
indication), allows to include in the analysis only complete records. In fact, we found only 1 case 
for OLI and no SLI. However, it should be noted that we adopted the same strategy of analysis for 
alemtuzumab, that on the contrary had signal of disproportionality in our analysis. This finding 
cannot be disregarded and further studies on possible effects on liver enzymes should be planned 
by also including the new approved drug ocrelizumab.  
The case-by-case analysis performed on OLI and SLI events highlighted a concomitant use of 
symptomatic drugs such as baclofen, gabapentin, pregabalin and others, which have already been 
associated with DILI events by Bjornsson et al., (199). Presence of disease modifying treatments 
(DMTs) plus other symptomatic drugs raise concerns on possible synergic effects between 
therapies involved in DILI events: interactions between therapies as well as alterations of 
therapeutic effect cannot be completely excluded. In this complex scenario, another aspect that 
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should be investigated is represented by the general downregulation of immune system generated 
by MS therapies that may per se trigger the infections potentially responsible for liver damage.  
The complexity of DILI events deserves also evaluation of environmental and social habits. 
In fact, alcoholism and previous infections can influence future liver damage. These aspects were 
only partially covered in FAERS database so far. In fact, we were only able to detect previous 
hepatitis by assessing presence of specific drugs, and in our cases only few patients (at most 4) had 
HBV or HCV infection. New algorithm specifically devoted to assess DILI events in PhV database 
has been recently published in the literature, however additional validation is needed before 
applying this strategy on FAERS data (223). In the meanwhile, reporters should be as accurate as 
possible when they submit a new case reports to the FDA or after regulatory agencies. In fact, 
application of complex algorithms require as much as possible information that generally are not 
reported or are affected by incompleteness.  
Our results call for future studies in order to assess the role of MS therapies in DILI events. 
These studies should evaluate the role of other factors such as clinical history, concomitant 
therapies, comorbidities, and social habits in order to characterized the patients who experience 
liver damage, and define the role of different exposure in DILI occurrence.  
 
 5.3 Methodological consideration and limitations  
 
5.3.1 Evidence mapping strategy  
 
The first part explored available evidence on drug exposure and possible MS risk and some 
limitations should be recognized. Firstly, the search strategy developed to perform literature 
review could be not able to retrieve all published items. However, this weakness was partially 
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resolved by snowballing of selected reviews, which allowed to include some previously excluded 
records. Another limit in this filed is represented by the absence of MeSH terms specifically devote 
to study “MS drug induced” in both Pubmed and Embase databases. This together to the prior 
limit can affect our analysis. This limit was figure out by applying no type of study restrictions, this 
strategy allows to collects as much as possible articles. Additionally, it should be noted that 
concerns on possible role of drugs in neurodegenerative disorders is a relatively new area of 
research therefore the amount of missing records can be considered very low. We encourage 
authors to be as specific as possible in article classification in order to increase sensibility of future 
update of this review, meanwhile new specific MeSH strategies for this topic should be included in 
the Mesh list of above databases.  
Analysis of pooled data from different studies was not possible due to variability of study 
designs included in the review. As showed by the quality assessments, many studies present 
several weaknesses, which should be taken into account in future studies in the same area of 
research. In particular, absence or incomplete data on patients selection, exposure assessment 
and study design did not allow comparison between the studies. Therefore, future studies on the 
same class of drugs should take into account weakness of previous studies trying to level out 
previously discrepancies. In addition, according with relevance of this possible “risk factor” authors 
should provide a minimum set of data which can be used for future meta-analysis or at least to 
compare results in accordance with peculiarities of each study. The last remark is about the 
importance of open-data. Recently, an increased number of editors required publication of the 
anonymous database used for the analysis together with relevant article. Sharing of data can 
contribute to reanalyze them by other authors clarify adopted strategy of analysis and may 
contribute to test new ones.  
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Nature of retrieved case reports and case series allowed only a general description of 
phenomenon. Also these piece of literature showed several missing data that have negative 
impact on evaluation of final association. Future case reports and case series should be more 
detailed, including previous therapies (also therapies not apparently involved in observed adverse 
event), co-morbidities and laboratory tests in order to pool case reports highlighting possible 
factors involved in the observed events.  
Nevertheless this study point out a new prospective in MS risk factor detection, giving an 
overview of available literature and providing some recommendations that should be taken into 
account in future studies. This effort can help future update of the present review and allows to 
pool data from single study in a more powerful studies. In addition, this review adds weight on 
importance to study the role of drugs in MS development. Finally, we would encourage authors to 
classify in a proper way their work by using more specific keywords. In the meantime scientific 
community should create new suitable MeSH more specific for this topic in order to increase the 
sensitivity of future research in the same area.  
 
5.3.2 Signal detection on FAERS database 
 
After having mapped already available clinical evidence on a possible role of drugs in MS 
occurrence, we explored the largest source of freely available adverse drug reaction reports 
namely FAERS database. The same source of data was used also to explore possible signal of DILI 
events during MS treatments. Results included in the part 2 and 3 of this thesis should be read 
taking into account some general and project-specific considerations according to the database 
characteristics. Firstly, the impact of Weber effect on our analysis. The Weber effect is a well-
known issue in pharmacovigilance studies. It is characterized by an increased number of reports of 
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adverse events during the first years of marketing of new agents (224). However, a recent 
publication focused on FAERS database highlighted the scarce impact of Weber effect in the last 
analysis due to huge number of reports included in the database during  the last years (225).  
Secondly, under reporting or over reporting can generate a misclassification of signals, 
increasing risk of notoriety bias (226). We developed ad hoc strategies of analysis taking in mind 
the specific characteristics of each study. As regards evaluation of MS after drug exposure we 
created ad hoc exclusion criteria in order to minimize misleading signals (i.e., signals for drugs used 
to treat patients already affected by MS). For this reason we excluded from the analysis: 1) cases 
with drugs specifically approved for MS treatment (i.e. interferons); 2) cases reported other drugs 
but with “Multiple Sclerosis” as reason for their use; 3) cases with vaccines because those are 
better studied in a dedicated database (VAERS). In addition, in order to prioritized the signals we 
focused only on drugs with: 1) significant ROR, 2) at least 10 cases, and 3) adequate cleaning index 
(≥70%). In pharmacovigilance studies, significant ROR with at least 3 cases is the minimum 
requirement to claim for a new signal (227), in this study we adopted strictly criteria in order to 
avoid misclassification of signals focusing on new potential signals that should be further 
investigated in future studies. As regards the study on DILI events during MS treatments, we were 
aware that DILI is generally a rare and severe condition that requires specific laboratory tests and 
clinical evaluation and that has several ways to be classified even if all of them indicate a severe 
medical condition. For this reason we planned two different strategies of analyses, one more 
inclusive and generic that include several preferred terms (OLI) and one that included only severe 
clinical conditions (SLI) by using few PTs.  
Misspelling errors can affect ability to codify drugs as well medical terms or other relevant 
information in pharmacovigilance databases. It should be noted that generally this does not 
represent a real issue for medical events, which are codify by using MedDRA dictionary. On the 
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contrary several errors can be detected in drugs information dataset. In fact, this dataset include a 
free text variable and a complex datamining procedure is needed in order to make suitable this 
information. Our data mining approach includes: a) elimination of word which do not indicate a 
drug (i.e., articles, verbs, unspecific words); b) application of Leveshtein distance strategy in order 
to replace misspelling error in specific letter with right one; c) codification of retrieved drugs by 
applying an “home-made” substance vocabulary (derived from previously codification of FAERS 
database); d) manually identification and codification of drugs (presenting at least 100 cases) 
which are still not codified with subsequent update of home-made vocabulary. The use of 
mentioned vocabulary is essential for several reasons, among those the most important are: fast 
codification of drugs in new version of FAERS, link each substance with relevant ATC code and 
possibility to perform grouped ATC code analyses (i.e., ATCIII level analysis instead of ATCV level). 
The vocabulary is updated accordingly to the new FAERS quartiles database. However, sometime 
selection of cases by using only substance name can generate an overestimation of phenomenon, 
therefore additional criteria in order to avoid false signal should be considered. For example, in 
the last study among the included drugs, there were two of them which had different indications 
(daclizumab and alemtuzumab). In this case we used also other variables to increase sensitivity of 
our case selection, so we included only reports with 1) substance 
(alemtuzumab/daclizumab)+brand name or 2) substance + MS as indication.  
Finally, it should remember that other factors can be involved in observed adverse events, 
unfortunately, so far, evaluation of their role could be challenging in PhV studies. However, we can 
use the already included variables to adjust or stratify analyses performed by using FAERS 
database (sex, country, age, concomitant therapies, sometime indicated comorbidities, reporter, 
challenge and dechallenge information). In spite of the huge number of information included in 
the database application of specific algorithm such as Naranjo algorithm is almost impossible or 
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misleading due to incompleteness of data (188). This is true also for other algorithms generally 
used to test presence of other risk factors. For example, in the DILI study could be useful to 
indicate concomitant presence of other risk factors able to trigger DILI events and should be 
recognized that a specific tool (PV-RUCAM) has been already developed. However, more studies 
need in order to test its applicability in PhV database (223). Although a proper algorithm was not 
applicable in our data, we decide to investigate concomitant presence of drugs already classified 
as potentially DILI inducer or drugs usually used to treat hepatic infections. Future studies by 
including more detailed information for each report can allow a proper application of algorithms 
which will be useful to evaluate also the impact of other lifestyle factors such as alcoholism or 
other ones.  
We would to remark that pharmacovigilance studies do not represent risk estimation but 
only a signal evaluation that deserves further evaluations. In fact, pharmacovigilance findings can 
be used to drive further studies able to include more detailed data in order to confirm or disclaim 
previously signals from PhV reports.  
Pharmacovigilance studies and in particular studies based on FAERS database have also 
several strengths. FAERS database is a freely available source of data that allows to perform 
analysis with relatively low cost budget. In addition, this source of data collects reports worldwide 
without any restriction criteria therefore is less prone to have a selected population as happen 
during clinical trials. This database is a suitable source to conduct pharmacovigilance studies on 
rare and unpredictable ADR such as DILI, MS and long QT syndrome. Finally, characteristics of data 
allow to generate findings which can be generalized worldwide.  
As last remark considering the importance of continuous surveillance of new approved 
drugs, quality of records is essential. As we said before, everyone (clinicians, consumers and 
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pharmaceutical companies) can submit the reports, however usually they have several lacking or 
missing data. This does not represent a real problem in FAERS database due to huge amount of 
data, however can limit application of specific algorithms. Reporters should include as detailed 
information as possible in order to improve above weakness. Therefore we encourage people to 
submit complete reports including also lifestyle information together with already well filled drugs, 
indication and ADRs information.   
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6. FEATURE PERSPECTIVES 
 
Our findings add weight to hypothesis of possible role of drugs in multiple sclerosis 
development. In particular, by evidence mapping we retrieved and analyzed available evidence on 
this topic, in order to take the best of evidence from the already available findings and by the 
FAERS analysis we have new signals of possible association between previous drug exposure and 
new MS cases. Although both strategies of analysis have some limitations they should represent 
the first step to explore the role of drugs in adverse effect because of their availability to scientific 
community. Future studies by using drugs as cause of disease or proxy of previous and 
concomitant disease can provide new data on this controversy association contributing to clarify 
also possible mechanism of pathogenesis, which are still under-detected in this very complex 
mechanism of disease. Use of longitudinal studies, which take into account differences or 
weaknesses of previous studies, can help researcher to define a minimum of requirement 
necessary in order to conduct studies on drugs as MS risk factor. An example of this delivery is 
represented by the ongoing study conducted in Emilia-Romagna on antibiotic exposure and MS 
risk. Results from this study and similar ones are going to contribute also to identifyother possible 
causes of disease not yet detected.   
As regards safety of authorized and generally used therapies in MS, post marketing phase 
is crucial in order to detect possible ADR which were not properly detected during pre-marketing 
phase studies. This aspect is important for both clinicians and patients, in fact ADRs occurrence 
have also an impact on treatment adherence and wellness of patients and therefore should be 
continuously evaluated. In particular we aimed to assess possible signals of liver injury during MS 
treatments. Our results on 11 authorized drugs suggested a possible risk of DILI by MS drug 
treatments. Future studies can detect new signal associated with adverse effect in treated 
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individuals by using an update FAERS database with most recent months data in order to include in 
the analysis also new marketed drugs: ocrelizumab and cladibrine. Unexplored ADRs can be 
assessed by using original strategies of analysis such as selection of specific Preferred terms (PTs), 
as well as use of available standardized queries that are called SMQ in MedDRA dictionary. In fact, 
the huge number of data collected in the last years in FAERS and other databases and the raised 
awareness of clinicians and consumers about the importance of pharmacovigilance analysis 
contribute to generate more and more data on still unknown ADRs as well as rare ADRs. Results of 
pharmacovigilance concerning MS therapies can drive stakeholders during ongoing clinical trials on 
possible new MS therapies (i.e., on ublituximab, ponesimod and anti-aquaporin-4 antibody), 
towards an early detection of safety profile of new drugs, specifically on emerged signals of risk for 
similar already marketed drugs.  
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7. CONCLUSION  
 
In this thesis, we explored the role of drugs as possible risk factor in MS development by 
performing both literature review and pharmacovigilance analysis. From literature review 
contrasting results emerged, whereas new signals were generated by exploring FAERS database. In 
particular, drugs acting on immune and endocrine system as well as drug used to treat microbial 
infections showed interesting relationship with MS development and they should be further 
investigated in order to assess their role in MS (per se cause of disease or proxy of concomitant 
disease).  
As regard to MS therapies, we aimed to assess occurrence of DILI events. New signals have 
been found for some disease modifying treatments (alemtuzumab, fingolimod, teriflunomide) and 
symptomatic agent (farmpridine). Additionally, concomitant presence of other drugs already 
associated with hepatic adverse events raise concern on possible synergic effect between 
therapies. Therefore future studies should assess the role of MS therapies in DILI occurrence 
taking into account concomitant therapies and lifestyle conditions (i.e., smoking and alcohol) that 
can trigger the studied phenomenon. Finally, liver tests should be planned in treated patients 
especially in those who already experienced hepatic dysfunctions.  
This thesis highlighted the importance of pharmacovigilance studies in the field of 
neurodegenerative diseases. Signal detection findings can drive future longitudinal studies with 
more appropriate designs in order to confirm or disprove them. We encourage clinicians and 
consumers to submit as detailed and complete information as possible for each report in order to 
better characterizing the signals and to allow sensitivity analyses, which could be useful for clinical 
and regulatory decisions.  
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Abstract 
Introduction: 
The role of drugs in the occurrence of multiple sclerosis (MS) is perceived to be insufficiently 
investigated. 
Objective: 
The aim of this study was to map and assess the evidence on MS occurrence after drug exposure, 
in order to identify possible signals of causal association. 
Methods: 
A search strategy was performed in MEDLINE and Embase as of July 2016; references consistent 
with the aim of the study were analysed to extract relevant measures of causal association 
between drugs and MS. The Newcastle-Ottawa Scale and appropriate guidelines from the 
International Society for Pharmacoepidemiology (ISPE) and the International Society of 
Pharmacovigilance (ISoP) were used to assess the quality of included studies. 
Results: 
After screening 832 articles, 58 were selected (of which 14 were found by checking the reference 
lists of reviews): 30 case reports and case series, 24 longitudinal studies and four randomized 
controlled trials. Seven longitudinal studies had good (at least 7 out of 9) quality scores, whereas 
case reports/case series presented several limitations. Half of included articles focused on 
immunomodulatory drugs (etanercept, infliximab and adalimumab), especially in case 
reports/series, suggesting an association with MS occurrence. Contraceptives and antibacterials 
were investigated in some population-based studies, without definite results. 
Conclusion: 
A heterogeneous pharmacological profile of identified classes emerged. Low strength of evidence 
and conflicting results highlighted the difficulties in addressing the possible contribution of drugs 
in MS occurrence. Methodological advances are needed, especially to control the confounding role 
of underlying disease for specific drug classes.
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Abstract 
Background: 
Possible relationship between drug exposure and multiple sclerosis (MS) development is 
insufficiently investigated, and further challenged by the incomplete understanding of MS 
etiopathogenesis. The study aims to investigate whether drug exposure could contribute to MS, by 
analyzing worldwide spontaneous reporting archives of adverse drug reaction (ADRs). 
Research design and methods: 
We retrieved information from the US Food and Drug Administration Adverse Event Reporting 
System (FAERS) over a 13-year period. Reporting odds ratio (ROR) for MS was calculated for each 
single substance. Disproportionality signals were considered when at least 10 cases were retrieved 
with a lower limit of the 95% confidence interval (CI) >1. 
Results: 
After a customized data-mining process, 3,226 reports of MS were retrieved. 'Antineoplastic and 
immunomodulating drugs' (33% of total reports) were the most frequently reported, with 10 
disproportionality signals, including etanercept (445 cases; ROR: 2.48; 95% Cl: 2.24-2.74), 
adalimumab (329; 2.05; 1.83-2.30), and infliximab (119; 2.25; 1.87-2.70). We also observed signals 
for drugs acting on hormone balance, bone density, and central nervous system. 
Conclusion: 
Our findings suggest that immunomodulatory drugs increase the risk of MS and point out that 
some other drug classes should be further investigated for this risk. 
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Abstract 
Background: 
Drug-induced liver injury (DILI) has been observed in patients with multiple sclerosis (MS), raising 
concerns on the liver safety of MS drugs. 
Objective: 
To describe DILI events with MS drugs by analyzing the FDA Adverse Event Reporting System. 
Methods: 
DILI reports were extracted and classified in overall liver injury (OLI), including asymptomatic 
elevation of liver enzymes, and severe liver injury (SLI). We performed disproportionality analysis 
by calculating adjusted reporting odds ratios (RORs) with 95% confidence interval (CI) and case-by-
case evaluation for concomitant drugs with hepatotoxic potential. 
Results: 
Fampridine showed statistically significant ROR for both OLI and SLI, whereas teriflunomide and 
fingolimod generated solid disproportionality (ROR > 2) only for OLI (ROR, 2.31; 95% CI, 2.12-2.52; 
and 2.53; 2.40-2.66, respectively). Among monoclonal antibodies, only alemtuzumab generated 
higher-than-expected ROR for OLI (1.34; 1.09-1.65). We also detected the expected hepatotoxic 
potential of beta interferon and mitoxantrone. Concomitant reporting of hepatotoxic drugs ranged 
from 26% (dimethyl fumarate) to 90% (mitoxantrone). 
Conclusion: 
These real-world pharmacovigilance findings suggest that DILI might be a common feature of MS 
drugs and call for (1) formal population-based study to verify the risk of fampridine and (2) 
awareness by clinicians, who should assess the possible responsibility of MS drugs when they 
diagnose DILI. 
